

CITATION REPORT

List of articles citing

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

DOI: 10.1016/s0140-6736(15)01281-7
Lancet, The, 2016, 387, 1540-1550.

Source: <https://exaly.com/paper-pdf/65388449/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2266	Current state of immunotherapy for non-small cell lung cancer. 2017 , 6, 196-211		107
2265	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. 2017 , 6, 178-185		16
2264	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. 2017 , 6, 186-195		8
2263	Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. 2016 , 2016,		1
2262	Immuntherapie bei Lungenkrebs. 2016 , 3, 60-68		
2261	Immune checkpoint inhibition in patients with brain metastases. 2016 , 4, S9		27
2260	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. 2016 , 9, 5855-5866		8
2259	-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. 2017 , 10, 101-112		43
2258	New targeted treatments for non-small-cell lung cancer - role of nivolumab. 2016 , 10, 103-17		18
2257	Lung cancer in Brazil: epidemiology and treatment challenges. 2016 , 7, 141-148		10
2256	Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. 2016 , 7, 20282-92		19
2255	PD-L1 expression in lung cancer. 2016 , 8, 3053-3055		1
2254	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. 2016 , 5, 628-636		12
2253	Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?. 2016 , 5, 538-542		4
2252	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. 2016 , 5, 720-726		24
2251	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. 2016 , 5, 301-21		33
2250	Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. 2016 , 2016, 2138627		18

2249	Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). 2016 , 205, 418-424	20
2248	Potential role of immunotherapy in advanced non-small-cell lung cancer. 2017 , 10, 21-30	33
2247	Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. 2016 , 7, 1599-1604	7
2246	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. 2016 , 6, 1629-40	138
2245	Focus on Alectinib and Competitor Compounds for Second-Line Therapy in -Rearranged NSCLC. 2016 , 3, 65	4
2244	Recent Advances in Immunotherapy in Metastatic NSCLC. 2016 , 6, 239	23
2243	Advances in Cancer Immunotherapy in Solid Tumors. 2016 , 8,	109
2242	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. 2016 , 17,	41
2241	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. 2016 , 10, 3153-3161	19
2240	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. 2016 , 9, 5101-16	26
2239	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. 2016 , 7, 74350-74361	31
2238	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. 2016 , 4, 215	6
2237	Pembrolizumab (Keytruda). 2016 , 12, 2777-2789	127
2236	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. 2016 , 21, 974-80	52
2235	Immunoth�rapie : un nouveau paradigme dans la prise en charge du cancer bronchique non ^ petites cellules. 2016 , 18, 365-370	1
2234	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study. 2016 , 122, 3024-31	56
2233	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. 2016 , 34, 596-603	35
2232	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. 2016 , 129, 453-460	61

2231	Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer. 2016 , 34, 2953-5	11
2230	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. 2016 , 29, 1165-72	269
2229	The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. 2016 , 100, 212-4	19
2228	Immune-Related Adverse Events From Immune Checkpoint Inhibitors. 2016 , 100, 242-51	66
2227	Immune Checkpoint Blockade in Melanoma Patients Induces Thyroid Autoimmune Disease. 2016 , 28, 299-302	
2226	AACR Cancer Progress Report 2016. 2016 , 22 Suppl 19, S1-S137	27
2225	Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. 2016 , 8, 1383-1391	14
2224	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. 2016 , 11, 385-390	27
2223	Immunotherapy for Lung Cancer. 2016 , 39, 360-8	9
2222	Biochemistry of Oxidative Stress. 2016 ,	3
2221	Overview and management of toxicities of immune checkpoint-blocking drugs. 2016 , 7, 28-37	1
2220	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). 2016 , 4,	78
2219	Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. 2016 , 11, 2048-2050	34
2218	Emerging therapeutic agents for lung cancer. 2016 , 9, 138	65
2217	MicroRNA-profiles in lung adenocarcinomas. 2016 , 1, 469-474	
2216	Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1. 2016 , 18, 501-508	1
2215	A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. 2016 , 95, e5539	30
2214	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. 2016 , 16, 434	93

2213	Rationale of an economically driven PD1 biomarker development in lung cancer—an academic dilemma. 2016 , 9, 109-110	1
2212	Immune Therapy for Prostate Cancer. 2016 , 22, 334-341	10
2211	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. 2016 , 4, 84	72
2210	Traitement de seconde ligne et au-delà des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogénique. 2016 , 8, 361-372	
2209	Prise en charge des métastases cérébrales des carcinomes bronchiques. 2016 , 8, 425-433	
2208	Les cancers bronchiques non à petites cellules EGFR-mutés. 2016 , 8, 373-381	
2207	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. 2016 , 34, 347-54	43
2206	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. 2016 , 9, 47	221
2205	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. 2016 , 76, 925-45	100
2204	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. 2016 , 22, 4585-93	655
2203	Emerging molecular classifications and therapeutic implications for gastric cancer. 2016 , 35, 49	28
2202	PD-L1 Expression in Lung Cancer. 2016 , 11, 964-75	201
2201	Targeting PD-L1 for non-small-cell lung cancer. 2016 , 8, 747-58	10
2200	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). 2016 , 27, 1492-504	280
2199	Into the Clinic With Nivolumab and Pembrolizumab. 2016 , 21, 527-8	10
2198	The role of neoantigens in response to immune checkpoint blockade. 2016 , 28, 411-9	88
2197	Emerging Opportunities and Challenges in Cancer Immunotherapy. 2016 , 22, 1845-55	172
2196	Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. 2016 , 17, 350-361	83

2195	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. 2016 , 21, 634-42	274
2194	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. 2016 , 27, 1291-8	91
2193	Current Challenges in Cancer Treatment. 2016 , 38, 1551-66	318
2192	Perspectives for immunotherapy in endocrine cancer. 2016 , 23, R469-84	10
2191	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. 2016 , 4, 48	145
2190	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. 2016 , 48, 1131-41	233
2189	Reply: The PD-1-PD-L1 Axis in Chronic Obstructive Pulmonary Disease. 2016 , 194, 644-5	5
2188	A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. 2016 , 115, 784-8	10
2187	A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform. 2016 , 11, 1863-1868	65
2186	The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. 2016 , 10, 1229-1241	9
2185	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. 2016 , 101, 4431-4439	129
2184	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. 2016 , 17, 2253-2266	22
2183	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. 2016 , 17, 1497-1508	954
2182	Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer. 2016 , 480, 160-165	9
2181	Immunotherapy for rectal carcinoma: Some stimulating data but still a long way to clinical evidence. 2016 , 68, 70-72	
2180	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. 2016 , 37, 771-782	8
2179	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. 2016 , 37, 760-770	33
2178	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. 2016 , 22, 5642-5650	98

2177	Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?. 2016 , 28, 726-731	6
2176	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. 2016 , 375, 1823-1833	5381
2175	Divide and Conquer to Treat Lung Cancer. 2016 , 375, 1892-1893	12
2174	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. 2016 , 11, 95	128
2173	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. 2016 , 16, 1479-1489	10
2172	Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery?. 2016 , 16, 1131-1144	
2171	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. 2016 , 99, 79-87	85
2170	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. 2016 , 16, 903-10	5
2169	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. 2016 , 18, 59	28
2168	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. 2016 , 4, 755-65	25
2167	[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. 2016 , 37, 557-567	31
2166	Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. 2016 , 11, 1927-1939	42
2165	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. 2016 , 5, 2567-78	45
2164	PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?. 2016 , 22, 4539-41	31
2163	Chemotherapy remains an essential element of personalized care for persons with lung cancers. 2016 , 27, 1829-35	52
2162	PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. 2016 , 36, 317-34	57
2161	Lymphocyte-activation gene-3, an important immune checkpoint in cancer. 2016 , 107, 1193-7	115
2160	Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. 2016 , 99, 41-5	24

2159	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. 2016 , 11, 2066-2081	40	
2158	Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. 2016 , 27, 1966-9	19	
2157	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet, The</i> , 2016 , 388, 1002-11	40	113
2156	New and emerging targeted treatments in advanced non-small-cell lung cancer. <i>Lancet, The</i> , 2016 , 388, 1012-24	40	299
2155	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. 2016 , 12, 1255-61	9	
2154	Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harboring Targetable Oncogenic Driver Mutations. 2016 , 76, 1321-36	14	
2153	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. 2016 , 11, 1387-96	6	
2152	Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. 2016 , 27, 1953-8	195	
2151	Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?. 2016 , 17, 54	13	
2150	Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. 2016 , 100, 38-44	4	
2149	Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. 2016 , 5, 119-122	5	
2148	Lung cancer in 2016: immunotherapy comes of age. 2016 , 4, 947-949	9	
2147	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. 2016 , 9, 939-49	9	
2146	Novel immunotherapy in the treatment of advanced non-small cell lung cancer. 2016 , 9, 1571-1581	18	
2145	Update in Lung Cancer 2015. 2016 , 194, 661-71	10	
2144	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. 2016 , 8, 460-473	26	
2143	A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer. 2016 , 100, 672-684	8	
2142	Lung cancer: First-line immunotherapy in lung cancer - taking the first step. 2016 , 13, 595-6	3	

2141	Management of non-small cell lung cancer in the era of personalized medicine. 2016 , 78, 173-179	18
2140	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. 2016 , 22, 4550-5	55
2139	Immunotherapie des Lungenkarzinoms. 2016 , 13, 249-254	
2138	Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. 2016 , 99, 162-5	31
2137	Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. 2016 , 30, 397-405	31
2136	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. 2016 , 16, 1209-23	14
2135	Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. 2016 , 16, 1217-1218	2
2134	Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer. 2016 , 16, 1541-1547	2
2133	Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. 2016 , 1, e000081	5
2132	Combination approaches in NSCLC involving immune checkpoint inhibitors. 2016 , 5, 163-171	1
2131	Making urothelial carcinomas less immune to immunotherapy. 2016 , 34, 534-537	1
2130	Targeting the PD-1/PD-L1 axis in the treatment of lung cancer. 2016 , 7, 17-27	
2129	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. 2016 , 4, 60	46
2128	Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). 2016 , 18, 533-542	2
2127	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. 2016 , 17, 1661-1671	86
2126	Diminished but not dead: chemotherapy for the treatment of NSCLC. 2016 , 17, 1464-1465	14
2125	PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. 2016 , 9, 201-206	28
2124	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. 2016 , 17, 59	3

2123	Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. 2016 , 102, 65-73	61
2122	Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered. 2016 , 14, 935-8	1
2121	Zielgerichtete und immunologische Therapie beim NSCLC. 2016 , 19, 56-62	
2120	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2016 , 27, v1-v27	590
2119	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" Napoli, December 5th 2015. 2016 , 4,	78
2118	Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. 2016 , 31, 238-42	1
2117	Immuntherapie bei fortgeschrittenem NSCLC. 2016 , 19, 28-28	
2116	Best Practices in Treatment Selection for Patients With Advanced NSCLC. 2016 , 23, 2-14	5
2115	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. 2016 , 43, 1954-61	87
2114	Harnessing the antitumor immunity cycle to treat lung cancer. 2016 , 5, 40-48	
2113	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. 2016 , 17, 984-993	498
2112	Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. 2016 , 8, 999-1009	26
2111	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. 2016 , 29, 1028-37	62
2110	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. 2016 , 28, e127-38	30
2109	Recent results of immunotherapy and perspectives for advanced NSCLC. 2016 , 5, 57-60	
2108	Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. 2016 , 11, 1003-11	112
2107	Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. 2016 , 22, 3713-7	49
2106	Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not. 2016 , 97, 15-21	32

2105	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. 2016 , 57, 1607-1611	84
2104	Second- and third-generation ALK inhibitors for non-small cell lung cancer. 2016 , 9, 19	88
2103	Targetless T cells in cancer immunotherapy. 2016 , 4, 23	21
2102	Immune Checkpoint Inhibitors in Older Adults. 2016 , 18, 47	40
2101	Anti-PD-L1 therapy: patient selection is important. 2016 , 13, 134-134	
2100	Scientific Advances in Lung Cancer 2015. 2016 , 11, 613-638	164
2099	Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. 2016 , 17, 169-76	15
2098	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. 2016 , 17, 18	14
2097	Racotumomab for treating lung cancer and pediatric refractory malignancies. 2016 , 16, 573-8	14
2096	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. 2016 , 101, 75-85	84
2095	Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. 2016 , 11, 976-88	161
2094	Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer. 2016 , 16, 747-58	10
2093	Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. 2016 , 15, 235-47	358
2092	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. 2016 , 22, 2102-4	26
2091	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2016 , 10, 183-93	90
2090	Recent advances in the management of pulmonary sarcomatoid carcinoma. 2016 , 10, 407-416	13
2089	FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer. 2017 , 123, 191	1
2088	Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. 2017 , 13, 195-207	381

2087	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. 2017 , 30, 577-586	88
2086	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. 2017 , 33, 749-759	50
2085	Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?. 2017 , 26, 207-217	12
2084	Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. 2017 , 53, 128-137	91
2083	EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. 2017 , 18, 527-534.e1	86
2082	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?. 2017 , 29, 207-217	5
2081	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. 2017 , 73, 1-8	279
2080	PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. 2017 , 17, 305-312	34
2079	Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. 2017 , 106, 1-7	294
2078	Beyond platinum treatment for NSCLC: what does the future hold?. 2017 , 17, 293-295	7
2077	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. 2017 , 309-327	1
2076	Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. 2017 , 96, 647-651	22
2075	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2017 , 35, 1341-1367	75
2074	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. 2017 , 18, 295-304	10
2073	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. 2017 , 174, 1-21	87
2072	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. 2017 , 15, 1	116
2071	Smokeless tobacco product may increase mortality rate in patients with prostate cancer. 2017 , 123, 190	
2070	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. 2017 , 19, 761-768	8

2069	Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer. 2017 , 23, 3585-3591	215
2068	An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. 2017 , 12, 791-803	85
2067	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 $\geq 50\%$ Expression in Lung Adenocarcinoma. 2017 , 12, 878-883	94
2066	Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. 2017 , 105, 17-22	36
2065	LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. 2017 , 23, 3316-3324	28
2064	Targeting ALK: Precision Medicine Takes on Drug Resistance. 2017 , 7, 137-155	269
2063	Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. 2017 , 18, 444-459.e1	56
2062	Cardiovascular Toxicities Associated with Cancer Immunotherapies. 2017 , 19, 21	99
2061	[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. 2017 , 37, 46-54	1
2060	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. 2017 , 75, 141-149	66
2059	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. 2017 , 17, 387-394	89
2058	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. 2017 , 6, e1286437	21
2057	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. 2017 , 25, 1713-1739	82
2056	[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. 2017 , 37, 61-78	10
2055	PD-1 and PD-L1 antibodies in cancer: current status and future directions. 2017 , 66, 551-564	188
2054	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. 2017 , 376, 1015-1026	1788
2053	MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential. 2017 , 6, e1280645	15
2052	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. 2017 , 7, 44173	50

2051	Standard of care in immunotherapy trials: Challenges and considerations. 2017 , 13, 2164-2178	4
2050	Assays for PD-L1 Expression: Do All Roads Lead to Rome?. 2017 , 3, 1058-1059	4
2049	EGFR TKI combination with immunotherapy in non-small cell lung cancer. 2017 , 16, 465-469	104
2048	Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. 2017 , 22, 470-479	166
2047	Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials. 2017 , 26, 415-426	4
2046	The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. 2017 , 17, 565-571	22
2045	The safety of second-line treatment options for non-small cell lung cancer. 2017 , 16, 471-479	2
2044	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. 2017 , 18, 623-630	320
2043	Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. 2017 , 9, 261-272	24
2042	Looking back and to the future: 'Are we improving 'cure' in non-small cell lung cancer?. 2017 , 75, 192-194	10
2041	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. 2017 , 92, 283-290	31
2040	Candidate immune biomarkers for radioimmunotherapy. 2017 , 1868, 58-68	13
2039	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. 2017 , 6, e1278100	54
2038	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. 2017 , 5, 312-318	259
2037	The squamous situation: Ancillary testing in pulmonary squamous cell carcinoma and implications for cytology laboratories. 2017 , 125, 153-154	
2036	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. 2017 , 106, 70-75	26
2035	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. 2017 , 12, 814-823	122
2034	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. 2017 , 45, 160-169	220

2033	Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. 2017 , 19, 5	
2032	Designing nanomedicine for immuno-oncology. 2017 , 1,	138
2031	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. 2017 , 10, 64	20
2030	Checkpoint Blockade in Lung Cancer and Mesothelioma. 2017 , 196, 274-282	42
2029	Emerging challenges of advanced squamous cell lung cancer. 2016 , 1, e000129	4
2028	Biological therapies in nonsmall cell lung cancer. 2017 , 49,	29
2027	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. 2017 , 13, 1159-1171	12
2026	Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data. 2017 , 141, 1018-1028	79
2025	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. 2017 , 18, 572-582.e1	39
2024	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. 2017 , 12, 153-161	20
2023	Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. 2017 , 66, 927-939	52
2022	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. 2017 , 78, 16-23	75
2021	Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. 2017 , 108, 217-221	25
2020	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer. 2017 , 23, 4569-4577	65
2019	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. 2017 , 22, 690-697	17
2018	Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. 2017 , 28, 1532-1539	167
2017	Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab. 2017 , 93, 62-66	10
2016	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. 2017 , 5, 417-424	241

2015	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. 2017 , 28, 1388-1398	54
2014	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. 2017 , 109, 1-8	19
2013	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. 2017 , 28, 874-881	144
2012	Current status of research and treatment for non-small cell lung cancer in never-smoking females. 2017 , 18, 359-368	43
2011	Immune checkpoint inhibitors in lung cancer: an update. 2017 , 13, 955-959	4
2010	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. 2017 , 152, 271-281	249
2009	Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?. 2017 , 79, 149-151	8
2008	Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. 2017 , 18, 682-691.e5	57
2007	Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. 2017 , 12, 1085-1097	128
2006	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. 2017 , 9, 507-520	8
2005	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. 2017 , 429, 1767-1786	12
2004	Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. 2017 , 106, 1-2	6
2003	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. 2017 , 195, 1150-1160	57
2002	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. 2017 , 77, 2318-2327	153
2001	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. 2017 , 11, 469-479	9
2000	Programmed cell death ligand 1 as a biomarker in head and neck cancer. 2017 , 125, 529-533	1
1999	Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction. 2017 , 12, 770-772	1
1998	Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis. 2017 , 16, 1588-1595	16

1997	The next generation of immunotherapy: keeping lung cancer in check. 2017 , 10, 87	63
1996	Immunotherapy in Lung Cancer. 2017 , 31, 131-141	26
1995	Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. 2017 , 31, 31-44	6
1994	Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies. 2017 , 140, 1609-1619	11
1993	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. 2017 , 12, 208-222	812
1992	Real-world data on nivolumab treatment of non-small cell lung cancer. 2017 , 56, 438-440	36
1991	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. 2017 , 93, 1-14	6
1990	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. 2017 , 23, 3158-3167	301
1989	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. 2017 , 14, 1248-1260	10
1988	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. 2017 , 3, e171029	46
1987	More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer. 2017 , 28, 685-687	1
1986	PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations. 2017 , 25, 1-3	8
1985	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. 2017 , 81, 116-129	314
1984	Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?. 2017 , 125, 591-593	3
1983	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. 2017 , 153, 812-826	371
1982	PD-L1 Expression in Pancreatic Cancer. 2017 , 109,	26
1981	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. 2017 , 12, 563-569	50
1980	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. 2017 , 57, 36-49	185

1979	Evaluation of dosing strategy for pembrolizumab for oncology indications. 2017 , 5, 43	127
1978	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. 2017 , 102, 2770-2780	125
1977	Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. 2017 , 22, 737-742	56
1976	Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression. 2017 , 37, 3475-3483	15
1975	Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. 2017 , 376, 2483-2485	22
1974	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. 2017 , 6, e1339856	6
1973	The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. 2017 , 28, 2256-2263	54
1972	PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. 2017 , 28, 882-889	77
1971	Pembrolizumab for Advanced Urothelial Carcinoma. 2017 , 376, 2302	8
1970	In Vivo Imaging of the Programmed Death Ligand 1 by F PET. 2017 , 58, 1852-1857	60
1969	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. 2017 , 18, 33	9
1968	Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. 2017 , 18, 36	14
1967	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. 2017 , 18, 895-903	577
1966	Programmed cell death-1/Programmed cell death ligand-1(PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). 2017 , 12, 6-13	8
1965	Checkpoint inhibitors for the treatment of non-small-cell lung cancer: news from the 2016 European Society for Medical Oncology Annual Congress. 2017 , 33, 126-132	1
1964	DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. 2017 , 110, 26-31	44
1963	Combining radiotherapy with immunotherapy: the past, the present and the future. 2017 , 90, 20170157	60
1962	Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. 2017 , 25, 453-459	109

1961	Immunotherapies for Lung Cancer. 2017 , 15, 692-695	4
1960	Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. 2017 , 49, 85-94	21
1959	Evaluation of the VeriStrat serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. 2017 , 109, 101-108	24
1958	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. 2017 , 3,	16
1957	Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. 2017 , 44, 403-414	66
1956	Understanding the checkpoint blockade in lung cancer immunotherapy. 2017 , 22, 1266-1273	36
1955	Scientific Advances in Thoracic Oncology 2016. 2017 , 12, 1183-1209	29
1954	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. 2017 , 9, 579-587	10
1953	Pembrolizumab-induced pneumonitis. 2017 , 3,	26
1952	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. 2017 , 22, 627-630	49
1951	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. 2017 , 17, 647-655	10
1950	A Pharmacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. 2017 , 109,	48
1949	Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types. 2017 , 18, 556-557	18
1948	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. 2017 , 18, 599-610	215
1947	Highlights on immune checkpoint inhibitors in non-small cell lung cancer. 2017 , 39, 1010428317695013	15
1946	Drug-biomarker co-development in oncology - 20 years and counting. 2017 , 30, 48-62	38
1945	Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. 2017 , 31, 1048-1051	61
1944	Milestones in the systemic treatment of lung cancer. 2017 , 10, 22-26	6

1943	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. 2017 , 18, 559-564	8
1942	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. 2017 , 995, 97-125	69
1941	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. 2017 , 46, 210-219	71
1940	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. 2017 , 15, 55	43
1939	Overview of Basic Immunology for Clinical Investigators. 2017 , 995, 1-31	4
1938	PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. 2017 , 66, 865-876	94
1937	Prospects and progress of atezolizumab in non-small cell lung cancer. 2017 , 17, 781-789	11
1936	Pembrolizumab for the treatment of non-small cell lung cancer. 2017 , 17, 399-409	24
1935	PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. 2017 , 7, 46209	25
1934	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. 2017 , 23, 4242-4250	513
1933	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. 2017 , 16, 573-585	16
1932	Comorbidities in the management of patients with lung cancer. 2017 , 49,	42
1931	Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas. 2017 , 9, 411-421	2
1930	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. 2017 , 18, 587-598	194
1929	Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. 2017 , 9, 423-433	6
1928	Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. 2017 , 108, 72-74	21
1927	Predictive biomarkers along gastric cancer pathogenetic pathways. 2017 , 17, 417-425	22
1926	Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. 2017 , 18, 595-606	34

1925	Immunotherapy. 2017 ,	4
1924	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. 2017 , 5, 12	121
1923	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. 2017 , 5, 29-41	190
1922	Current progress in immunotherapy of hepatocellular carcinoma. 2017 , 66, 482-484	36
1921	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. 2017 , 28, 583-589	348
1920	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. 2017 , 9, 5-8	18
1919	Immuno-Oncology: The Third Paradigm in Early Drug Development. 2017 , 12, 125-138	16
1918	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. 2017 , 12, 752-762	13
1917	Atypical autoimmune adverse effects with checkpoint blockade therapies. 2017 , 28, 206-207	11
1916	Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. 2017 , 18, 1-4	6
1915	Current Trends in Cancer Therapy. 2017 , 1-24	3
1914	Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. 2017 , 110, 1-12	50
1913	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. 2017 , 29, 218-230	37
1912	Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. 2017 , 41, 111-124	30
1911	Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. 2017 , 23, 3012-3024	442
1910	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. 2017 , 35, 243-252	15
1909	Rejection versus escape: the tumor MHC dilemma. 2017 , 66, 259-271	80
1908	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <i>Lancet, The</i> , 2017 , 389, 255-265	40 2681

1907	Programmed death of chemotherapy in non-small-cell lung cancer?. <i>Lancet, The</i> , 2017 , 389, 227-228	40	4
1906	High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases. 2017 , 67, 37-44		24
1905	Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer. 2017 , 77, 851-861		35
1904	The clinical development of vaccines for HER2 breast cancer: Current landscape and future perspectives. 2017 , 61, 107-115		21
1903	Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. 2017 , 9, 1175-1183		26
1902	S-1 as an option for second-line treatment of NSCLC. Is the 'East Side Story' applicable in the West?. 2017 , 28, 2627-2629		0
1901	Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. 2017 , 12, 1798-1805		241
1900	Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer. 2017 , 322, 26-33		8
1899	PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung. 2017 , 51, 357-362		28
1898	Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. 2017 , 125, 21-30		49
1897	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. 2017 , 2, e000236		19
1896	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. 2017 , 18, 1493-1501		544
1895	PD-L1 IHC in NSCLC with a global and methodological perspective. 2017 , 113, 102-105		25
1894	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. 2017 , 119, 30-39		29
1893	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. 2017 , 119, 1-12		105
1892	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. 2017 , 7, 1420-1435		302
1891	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. 2017 , 125, 896-907		119
1890	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. 2017 , 15, 205		13

1889 FEATURES. **2017**, 21, 16-27

1888 Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. **2017**, 96, 378-383 55

1887 [Not Available]. **2017**, 142, 1531-1534

1886 Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. **2017**, 17, 1055-1069 19

1885 [Lung cancer : What has been confirmed in therapy?]. **2017**, 58, 1258-1263 1

1884 LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. **2017**, 28, 2977-2984 93

1883 Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. **2017**, 86, 257-265 21

1882 ESMO-Magnitude of Clinical Benefit Scale version 1.1. **2017**, 28, 2340-2366 266

1881 Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). **2017**, 28, 2698-2706⁵¹

1880 Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression. **2017**, 20, 609-615 3

1879 Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer. **2017**, 21, 211-220 2

1878 Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. **2017**, 141, 1529-1532 15

1877 Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis. **2017**, 2, e000222 10

1876 FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. **2017**, 22, 1392-1399 150

1875 Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. **2017**, 18, 1477-1490 16

1874 Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. **2017**, 11, 353-373 19

1873 New Immunotherapy and Lung Cancer. **2017**, 53, 682-687 6

1872 Lung Cancer in the Older Patient. **2017**, 33, 563-577 13

1871	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. 2017 , 12, 1654-1663	68
1870	CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy. 2017 , 13, 2272-2279	
1869	PDL-1/PD1 inhibitors: antibody or antinobody?. 2017 , 13, 1669-1671	7
1868	Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. 2017 , 377, 849-861	376
1867	Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. 2017 , 68, 103-111	47
1866	ATS Core Curriculum 2017: Part IV. Adult Pulmonary Medicine. 2017 , 14, S196-S208	
1865	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. 2017 , 12, 709-718	13
1864	Trial watch: Immune checkpoint blockers for cancer therapy. 2017 , 6, e1373237	53
1863	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. 2017 , 23, 4950-4958	30
1862	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. 2017 , 85, 155-157	5
1861	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. 2017 , 57 Suppl 10, S26-S42	63
1860	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. 2017 , 60, 60-68	83
1859	PD-1 checkpoint inhibition: Toxicities and management. 2017 , 35, 701-707	44
1858	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. 2017 , 7, 11373	42
1857	Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. 2017 , 13, 2629-2644	7
1856	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. 2017 , 35, 1195-1209	14
1855	Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease. 2017 , 7, 604-608	12
1854	Neurological Complications of Immunotherapies-Beware of the Checkpoint Ahead. 2017 , 74, 1176-1177	1

1853	Atezolizumab for the treatment of non-small cell lung cancer. 2017 , 10, 935-945	21
1852	[Immunotherapy: Activation of a system not a pathway]. 2017 , 104, 462-475	
1851	Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. 2017 , 111, 182-189	20
1850	Cancer Immunotherapy in Older Patients. 2017 , 23, 219-222	14
1849	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. 2017 , 59, 71-78	65
1848	Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. 2017 , 14, 1568-1580	8
1847	Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. 2017 , 13, 277-288	31
1846	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. 2017 , 13, 296-303	12
1845	C�ncer de pulm�n no microc�tico. 2017 , 12, 1811-1824	
1844	Adenocarcinoma de pulm�n diseminado de dif�cil manejo. 2017 , 12, 1887.e1-1887.e3	
1843	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. 2017 , 44, 132-135	64
1842	Cancer Immunotherapies: Are They as Effective in the Elderly?. 2017 , 34, 567-581	22
1841	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. 2017 , 111, 6-11	2
1840	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. 2017 , 6, e1356145	177
1839	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. 2017 , 19, 62	11
1838	Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice. 2017 , 125, 521-528	7
1837	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge. 2017 , 83, 266-278	16
1836	Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. 2017 , 12, 1536-1543	41

1835	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. 2017 , 2, e000200	25
1834	Immunonkologie bei Brustkrebs. 2017 , 50, 546-550	
1833	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. 2017 , 29, 97-104	29
1832	Lung cancer as a cardiotoxic state: a review. 2017 , 34, 159	7
1831	Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. 2017 , 32, 300-312	35
1830	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. 2017 , 44, 2310-2325	34
1829	Recent Advances in Targeting ROS1 in Lung Cancer. 2017 , 12, 1611-1625	132
1828	Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. 2017 , 12, 571-597	97
1827	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. 2017 , 17, 75	13
1826	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. 2017 , 50,	192
1825	[Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs]. 2017 , 104, 807-811	0
1824	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. 2017 , 112, 90-95	128
1823	PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. 2017 , 112, 200-215	122
1822	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. 2017 , 19, 64	71
1821	Immunotherapy based approaches in myelofibrosis. 2017 , 10, 903-914	7
1820	Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. 2017 , 13 Suppl 3, 3-13	10
1819	EGFR tyrosine kinase inhibitors chemotherapy in wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. 2017 , 50,	12
1818	MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. 2017 , 6, e1338998	28

1817 Immunotherapy of Cancer. **2017**, 244-266

1816 Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review. **2017**, 120, 86-92

65

1815 [Current Aspects of Diagnosis and Treatment of Lung Cancer]. **2017**, 142, 1808-1812

3

1814 Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer. **2017**, 7, 16956

24

1813 New Immunotherapy and Lung Cancer. **2017**, 53, 682-687

3

1812 T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. **2017**, 8, 1747

240

1811 Quality matters: immunotherapy and the evolving landscape of advanced cancer care. **2017**, 2, 235-244

2

1810 Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia. *Lancet, The*, **2017**, 390, 2343-2345

40 87

1809 Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?. **2017**, 13, 2503-2505

7

1808 Personalised medicine for nonsmall cell lung cancer. **2017**, 26,

28

1807 Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. **2017**, 2, e000119

6

1806 Combining immunotherapies for the treatment of prostate cancer. **2017**, 35, 694-700

18

1805 Cardiotoxicity of immune checkpoint inhibitors. **2017**, 2, e000247

126

1804 Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes. **2017**, 112, 176-180

1

1803 Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis. **2017**, 96, e8407

8

1802 Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. **2017**, 19, 49

15

1801 Immune checkpoint inhibitors and elderly people: A review. **2017**, 82, 155-166

99

1800 Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. **2017**, 111, 65-68

13

1799	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. 2017 , 12, 475-485	23
1798	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. 2017 , 17, 779-786	24
1797	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2017 , 28, iv119-iv142	1100
1796	Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples. 2017 , 18, e473-e479	27
1795	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. 2017 , 405, 29-37	51
1794	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. 2017 , 23, 5737-5744	55
1793	What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016. 2017 , 13, 1427-1435	4
1792	Biomarkers of response to PD-1/PD-L1 inhibition. 2017 , 116, 116-124	185
1791	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. 2017 , 14, 655-668	498
1790	Assessing treatment efficacy in the subset of responders in a randomized clinical trial. 2017 , 28, 1640-1647	2
1789	Optimale Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIB/C. 2017 , 20, 32-42	
1788	Spotlight on landmark oncology trials: the latest evidence and novel trial designs. 2017 , 15, 111	2
1787	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. 2017 , 5,	8
1786	The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. 2017 , 9, 647-657	15
1785	Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review. 2017 , 9, 701-707	15
1784	A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. 2017 , 111, 1-5	43
1783	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. 2017 , 30, 1411-1421	114
1782	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. 2017 , 209, 567-575	22

1781 Immuncheckpointinhibitoren. **2017**, 23, 575-584

1780 Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence. **2017**, 27, 537-545 37

1779 Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. **2017**, 22, 3-11 29

1778 Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. **2017**, 12, 458-466 83

1777 Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. **2017**, 12, 281-292 66

1776 Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. **2017**, 17, 47-59 27

1775 Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. **2017**, 104, 131-133 7

1774 F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. **2017**, 97, 372-380 15

1773 Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. **2017**, 66, 45-50 44

1772 Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. **2017**, 13, 528-532 23

1771 A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. **2017**, 3, 256-259 133

1770 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. **2017**, 22, 81-88 95

1769 Lung cancer: current therapies and new targeted treatments. *Lancet, The*, **2017**, 389, 299-311 40 1358

1768 The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. **2017**, 12, 194-207 132

1767 Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. **2017**, 28, 44-56 24

1766 Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. **2017**, 28, 368-376 468

1765 Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. **2017**, 18, 100-103 7

1764 Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach. **2017**, 18, 220-233.e8 60

1763	Immunotherapy Comes of Age in Lung Cancer. 2017 , 18, 13-22	49
1762	W'ALK' Into the Next Stage. 2017 , 18, 122-126	5
1761	New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. 2017 , 109, 35-41	12
1760	Next generation predictive biomarkers for immune checkpoint inhibition. 2017 , 36, 179-190	67
1759	The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. 2017 , 103, 27-37	89
1758	The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. 2017 , 68, 153-168	20
1757	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. 2017 , 35, 709-717	587
1756	Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. 2017 , 22, 70-80	41
1755	Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population. 2017 , 96, e9519	2
1754	Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report. 2017 , 96, e9431	27
1753	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. 2017 , 96, e9320	7
1752	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. 2017 , 96, e8931	17
1751	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. 2017 ,	78
1750	Les cancers bronchiques non ^petites cellules EGFR-mut�s. 2017 , 9, 213-223	
1749	The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report. 2017 , 10, 752-757	27
1748	Prise en charge des patients de stade avanc� avec remaniement ALK : aujourd�hui et demain (� qui sera un autre jour... �). 2017 , 9, 224-233	
1747	Traitement de premi�re ligne et de maintenance dans les CBNPC avanc�s en l�absence d�addiction oncog�nique. 2017 , 9, 234-247	
1746	Cancer bronchique non ^petites cellules de stade IV sans addiction oncog�nique : traitements en 2 e ligne et au-del�. 2017 , 9, 248-258	

1745	Immunothérapie et cancer du poumon : où en sommes-nous ?. 2017 , 9, 315-324	0
1744	Les complications de l'immunothérapie. 2017 , 9, 325-331	1
1743	Altérations moléculaires anciennes et émergentes : quand les rechercher ?. 2017 , 9, 202-212	
1742	Les patients avec indice de performance supérieur à 1. 2017 , 9, 308-314	
1741	Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy. 2017 , 9, 769-779	9
1740	EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. 2017 , 28, iv84-iv99	157
1739	Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. 2017 , 6, 93-107	3
1738	Checkpointinhibitoren beim nichtkleinzelligen Lungenkarzinom. 2017 , 23, 838-844	
1737	Immuntherapie in der Onkologie. 2017 , 12, 17-33	1
1736	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. 2017 , 8, 58457-58468	35
1735	Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours). 2017 , 28, iv158-iv161	
1734	Caring for the Older Population With Advanced Lung Cancer. 2017 , 37, 587-596	6
1733	The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. 2017 , 1, 7-7	11
1732	Cancer Immunotherapy in Older Patients. 2017 , 23, 219-222	4
1731	Clinical use of immune checkpoint inhibitors. 2017 ,	
1730	A Case of Secondary Adrenocortical Insufficiency Developed due to ACTH Deficiency After Nivolumab Treatment. 2017 , 57, 226-231	0
1729	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. 2017 , 9, 741-750	14
1728	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. 2017 , 13, 223-236	15

1727	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. 2017 , 11, 787	24
1726	Cytostatic Agents: Monoclonal Antibodies Utilized in the Treatment of Solid Malignancies. 2017 , 39, 465-482	1
1725	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. 2017 , 8, 49	314
1724	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. 2017 , 8, 730	233
1723	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. 2017 , 13, 1259-1271	12
1722	Treating mutation resistance in non-small cell lung cancer - role of osimertinib. 2017 , 10, 49-56	18
1721	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. 2017 , 8, 259-269	25
1720	New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. 2017 , 8, 67-78	20
1719	Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. 2017 , 17, 378-391	50
1718	The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. 2017 , 8, 57826-57835	21
1717	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. 2017 , 6, 51-71	76
1716	Cost analysis of adverse events associated with non-small cell lung cancer management in France. 2017 , 9, 443-449	4
1715	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. 2017 , 11, 2537-2549	4
1714	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. 2017 , 7, 1-11	29
1713	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. 2017 , 8, 561	804
1712	CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. 2017 , 8, 269	34
1711	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. 2017 , 8, 1597	145
1710	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. 2017 , 18,	34

1709	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. 2017 , 4, 4	24
1708	Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. 2017 , 4, 36	9
1707	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. 2017 , 7, 38	12
1706	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. 2017 , 7, 50	21
1705	Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine. 2017 , 7, 52	22
1704	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. 2017 , 7, 67	25
1703	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. 2017 , 7, 197	18
1702	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. 2017 , 7, 230	31
1701	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. 2017 , 2017, 7694202	6
1700	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. 2017 , 2017, 5618174	8
1699	Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. 2017 , 9, 655-668	8
1698	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. 2017 , 10, 2513-2526	25
1697	Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. 2017 , 10, 2983-2992	34
1696	Role of afatinib in the treatment of advanced lung squamous cell carcinoma. 2017 , 9, 147-157	3
1695	Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma. 2017 , 10, 763-771	34
1694	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity. 2017 , 8, 57-66	2
1693	Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor. 2017 , 9, 6867	7
1692	Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. 2017 , 9, 601-609	15

1691	AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?. 2017 , 5, S14	3
1690	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. 2017 , 9, 207-213	90
1689	Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. 2017 , 8, 48248-48252	65
1688	Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2017 , 8, 93149-93155	45
1687	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. 2017 , 8, 66491-66503	1
1686	A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. 2017 , 9, 2560-2571	16
1685	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. 2017 , 12, e0181598	25
1684	Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. 2017 , 12, e0183023	50
1683	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. 2017 , 12, e0186106	12
1682	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. 2017 , 6, e1344805	97
1681	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. 2017 , 103, 405-421	31
1680	Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression. 2017 , 5, 181-185	0
1679	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. 2017 , 17, 618	25
1678	Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?. 2017 , 15, 173	29
1677	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. 2017 , 10, 136	33
1676	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. 2017 , 10, 146	57
1675	Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. 2017 , 5, 53	432
1674	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. 2017 , 5, 56	7

1673	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. 2017 , 5, 66	27
1672	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. 2017 , 5, 93	41
1671	Biomarkers for immunotherapy in bladder cancer: a moving target. 2017 , 5, 94	100
1670	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. 2017 , 5, 103	4
1669	Immunotherapie thorakaler Tumoren. 2017 , 20, 21-27	
1668	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. 2017 , 12, 403-407	432
1667	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. 2017 , 6, S8-S20	67
1666	Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, efficacy and Resistance. 2017 , 06,	
1665	Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma. 2017 , 7, 1-7	1
1664	Recent advances in the management of non-small cell lung cancer. 2017 , 6, 2110	16
1663	Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer. 2017 , 8, 58199-58209	9
1662	Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer. 2017 ,	
1661	Checkpoint Inhibitors in Nonsmall Cell Lung Cancer. 2017 ,	
1660	Atezolizumab in advanced non-small cell lung cancer. 2017 , 9, 3603-3606	6
1659	Lung cancer prognosis: can histological patterns and morphological features have a role in the management of lung cancer patients?. 2017 , 5, 353	9
1658	PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. 2017 , 8, 98524-98532	37
1657	Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. 2017 , 1, 133-141	8
1656	Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. 2017 , 8, 8738-8751	87

1655	PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. 2017 , 9, E384-E386	14
1654	Comparative effectiveness and safety of -paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. 2017 , 8, 179-190	6
1653	The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer. 2017 , 11, 3367-3376	4
1652	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. 2017 , 11, 2851-2860	25
1651	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. 2017 , 23, S34-S48	12
1650	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. 2017 , 23, 1208-1216	39
1649	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. 2017 , 8, 8910-8920	93
1648	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. 2017 , 7,	12
1647	Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011. 2017 , 24, e486-e493	11
1646	Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. 2017 , 8, 4075-4082	7
1645	Circulating Tumor Cells (CTCs) as Biomarker for PD-1/PD-L1 Blockade Immunotherapy. 2017 , 09,	
1644	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. 2017 , 8, 41641-41669	13
1643	Precision Oncology: Who, How, What, When, and When Not?. 2017 , 37, 160-169	66
1642	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. 2017 , 8, 8890-8899	37
1641	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. 2017 , 35, 3823-3829	298
1640	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 2017 , 35, 3484-3515	358
1639	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. 2017 , 35, 3449-3457	223
1638	Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade. 2017 , 35, 2735-2736	2

1637	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). 2017 , 35, 3924-3933	495
1636	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. 2017 , 35, 1542-1549	401
1635	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. 2017 , 35, 3867-3876	263
1634	Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. 2017 , 37, 630-639	7
1633	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. 2017 , 13, 832-837	37
1632	How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?. 2017 , 35, 2860-2862	
1631	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. 2017 , 1, 132-142	2
1630	A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC. 2017 , 9, E292-E294	
1629	Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. 2017 , 9, 655-665	11
1628	PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies. 2017 , 9, E470-E473	3
1627	Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. 2017 , 9, 1903-1910	15
1626	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. 2017 , 9, 2142-2158	62
1625	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. 2017 , 9, 2579-2586	32
1624	Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. 2017 , 9, 3123-3131	15
1623	The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis. 2017 , 9, 3480-3482	1
1622	KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer. 2017 , 9, 4187-4190	2
1621	Tumor-associated macrophages-additional effectors at anti-PD-1/PD-L1 therapy?. 2017 , 9, 4197-4200	4
1620	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. 2017 , 6, 373-386	32

1619	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. 2017 , 6, 570-587	26
1618	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. 2017 , 8, 83986-83994	45
1617	Immune checkpoint blockade for hematologic malignancies: a review. 2017 , 4, 32	44
1616	Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?. 2017 , 9, 2771-2773	2
1615	Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. 2017 , 9, 2812-2818	1
1614	Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed. 2017 , 9, 4821-4824	10
1613	Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them. 2017 , 6, S51-S54	7
1612	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 2017 , 1, 455-466	43
1611	Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. 2017 , 6, S41-S43	2
1610	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.. 2017 , 1, 1-15	31
1609	Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. 2017 , 8, 58887-58902	20
1608	Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. 2018 , 7, e1438111	75
1607	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. 2018 , 4, 522-528	56
1606	Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting. 2018 , 19, 360-370	19
1605	Targeting the microenvironment in solid tumors. 2018 , 65, 22-32	189
1604	Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. 2018 , 65, 65-77	25
1603	Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?. 2018 , 6, 250-254	3
1602	Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers. 2018 , 73, 68-80	17

1601	The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?. 2018 , 13, 291-294	17
1600	Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. 2018 , 17, 38	253
1599	Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. 2018 , 126, 264-274	60
1598	Time is up for PD-L1 testing standardization in lung cancer. 2018 , 29, 791-792	2
1597	Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. 2018 , 29, 1320-1324	21
1596	PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. 2018 , 11, 345-359	18
1595	Immunotherapy in Lung Cancer and the Role of Imaging. 2018 , 39, 314-321	2
1594	Cancer immunotherapy in patients with brain metastases. 2018 , 67, 703-711	11
1593	Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORO) 0809. 2018 , 41, 1113-1117	3
1592	Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition. 2018 , 6, 617-627	8
1591	Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer. 2018 , 110,	22
1590	Durvalumab in urothelial cancers. 2018 , 18, 311-318	6
1589	Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. 2018 , 126, 342-352	81
1588	Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers. 2018 , 14, 337-342	2
1587	Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. 2018 , 109, 814-820	24
1586	Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. 2018 , 8, 3941	7
1585	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. 2018 , 25, 1814-1827	30
1584	Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 2018 , 19, 352-359.e1	7

1583	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. 2018 , 7, 133-141	42
1582	Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma. 2018 , 118, 62-68	10
1581	Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. 2018 , 119, 112-119	9
1580	Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. 2018 , 119, 14-20	85
1579	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. 2018 , 27, 88-94	27
1578	Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. 2018 , 233, 6337-6343	65
1577	Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. 2018 , 81, 1105-1109	49
1576	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. 2018 , 59, 328-338	11
1575	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. 2018 , 120, 137-141	22
1574	Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. 2018 , 57, 1225-1231	42
1573	Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. 2018 , 9, 736-744	22
1572	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. 2018 , 3, e000344	60
1571	Emerging Systemic Therapies for Colorectal Cancer. 2018 , 31, 179-191	13
1570	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. 2018 , 378, 2078-2092	2820
1569	Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice. 2018 , 10, 1758835918768238	39
1568	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. 2018 , 10, 1758835918762094	74
1567	PD-L1 expression testing in non-small cell lung cancer. 2018 , 10, 1758835918763493	90
1566	Radiotherapy and checkpoint inhibitors: a winning new combination?. 2018 , 10, 1758835918768240	58

1565	Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer. 2018 , 143, 1741-1752	31
1564	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. 2018 , 19, e421-e430	28
1563	Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. 2018 , 56, 471-483	4
1562	Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. 2018 , 56, 485-495	42
1561	Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung. 2018 , 117, 1563-1569	15
1560	Monoclonal Antibody LMab-13 Detected Human PD-L1 in Lung Cancers. 2018 , 37, 110-115	31
1559	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. 2018 , 120, 62-69	18
1558	Clinical assessment of immune-related adverse events. 2018 , 10, 1758835918764628	74
1557	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. 2018 , 10, 1758835918763723	2
1556	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. 2018 , 66, 114-121	25
1555	Anti-Angiogenics: Their Value in Lung Cancer Therapy. 2018 , 41, 172-180	22
1554	Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. 2018 , 29, 1417-1422	61
1553	Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. 2018 , 120, 142-148	18
1552	Anti-Podocalyxin Monoclonal Antibody 47-mG Detects Lung Cancers by Immunohistochemistry. 2018 , 37, 91-94	2
1551	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. 2018 , 125, 41-47	19
1550	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. 2018 , 23, 1199-1209	25
1549	Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio. 2018 , 29, 521-522	
1548	Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. 2018 , 51,	7

1547	[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. 2018 , 105, 263-274	10
1546	Lung Cancer. 2018 , 1-21	
1545	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 13, 323-358	241
1544	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. 2018 , 118, 36-40	51
1543	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. 2018 , 18, 3	65
1542	Combining chemotherapy with PD-1 blockade in NSCLC. 2018 , 186, 130-137	56
1541	Central Nervous System Germinomas Express Programmed Death Ligand 1. 2018 , 77, 312-316	5
1540	Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. 2018 , 129, 130-135	47
1539	Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. 2018 , 64, 21-29	31
1538	[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma]. 2018 , 35, 197-205	3
1537	Immuno-oncology-101: overview of major concepts and translational perspectives. 2018 , 52, 1-11	30
1536	A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. 2018 , 11, 311-329	119
1535	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). 2018 , 118, 654-661	121
1534	Temozolomide-associated hypermutation in gliomas. 2018 , 20, 1300-1309	69
1533	Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. 2018 , 23, 634-640	71
1532	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. 2018 , 13, 1-20	23
1531	Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. 2018 , 29, i20-i27	54
1530	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 118, 321-346	371

1529	Cell death-based treatment of lung adenocarcinoma. 2018 , 9, 117	208
1528	The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. 2018 , 35, 25	79
1527	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. 2018 , 10, 1758834017749748	128
1526	Role of immune-checkpoint inhibitors in lung cancer. 2018 , 12, 1753465817750075	58
1525	PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy?. 2018 , 29, 1065-1066	25
1524	Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. 2018 , 29, 953-958	133
1523	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF- β . 2018 , 10,	239
1522	The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. 2018 , 14, 191-194	3
1521	Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). 2018 , 143, 45-51	52
1520	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. 2018 , 19, 405-415	236
1519	Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. 2018 , 420, 242-246	71
1518	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 33, 128-158	165
1517	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. 2018 , 8, 2592	57
1516	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. 2018 , 6, 402-408	42
1515	PD-L1 expression in large cell neuroendocrine carcinoma of the lung. 2018 , 118, 76-82	21
1514	Hypermutated Tumors and Immune Checkpoint Inhibition. 2018 , 78, 155-162	16
1513	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. 2018 , 19, 416-426	291
1512	Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer. 2018 , 53, 1205-1213	6

1511	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle. 2018 , 47, 142-157	16
1510	Checkpoint Inhibitors, Palliative Care, or Hospice. 2018 , 20, 2	8
1509	Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer. 2018 , 8, 1023	17
1508	Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. 2018 , 36, 509-512	20
1507	Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores. 2018 , 42, 687-694	21
1506	Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. 2018 , 24, 1271-1276	24
1505	E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer. 2018 , 592, 621-630	36
1504	PD-1/PD-L1 Axis in Lung Cancer. 2018 , 24, 15-19	39
1503	The biology and management of non-small cell lung cancer. 2018 , 553, 446-454	1499
1502	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. 2018 , 18, 267-276	11
1501	Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. 2018 , 19, 301-314	6
1500	Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. 2018 , 10, 85-91	25
1499	Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. 2018 , 495, 2344-2349	28
1498	Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. 2018 , 19, 280-288.e4	38
1497	Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. 2018 , 116, 62-66	69
1496	PD-L1 Expression in a Non-Small Cell Lung Cancer Specimen Obtained by EBUS-TBNA. 2018 , 54, 290-292	9
1495	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. 2018 , 100, 916-925	162
1494	PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. 2018 , 13, 447-453	28

1493	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. 2018 , 13, 165-183	52
1492	Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. 2018 , 13, 367-376	99
1491	Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer. 2018 , 13, 377-386	39
1490	Progress in the Management of Advanced Thoracic Malignancies in 2017. 2018 , 13, 301-322	34
1489	Changing health care costs for NSCLC, what does it mean?. 2018 , 117, 62-63	2
1488	Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura. 2017 , 10, 998-1005	6
1487	Pembrolizumab for the treatment of bladder cancer. 2018 , 18, 107-114	9
1486	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. 2018 , 23, 410-421	15
1485	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. 2018 , 13, 106-111	130
1484	Immune Checkpoint Inhibition in Lung Cancer. 2018 , 333-344	
1483	PD-L1 and Other Immunological Diagnosis Tools. 2018 , 371-385	2
1482	Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors. 2018 , 565-578	1
1481	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. 2018 , 126, 217-223	67
1480	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. 2018 , 4, 210-216	277
1479	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. 2018 , 118, 1599-1663	51
1478	Will liquid biopsies become our fluid transition to personalized immunotherapy?. 2018 , 29, 11-13	1
1477	Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. 2018 , 24, 2268-2275	53
1476	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). 2018 , 10, 1758834017745012	73

1475	Master protocols in lung cancer: experience from Lung Master Protocol. 2018 , 30, 92-97	10
1474	Improving immune-vascular crosstalk for cancer immunotherapy. 2018 , 18, 195-203	170
1473	Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors. 2018 , 25, 339-350	27
1472	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naïve and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. 2018 , 19, e335-e348	39
1471	Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report. 2018 , 48, e17-e20	5
1470	Inhibitors of the PD-1 Pathway in Tumor Therapy. 2018 , 200, 375-383	82
1469	Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. 2018 , 418, 1-9	39
1468	Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. 2018 , 19, e349-e358	36
1467	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. 2018 , 29, 301-310	56
1466	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. 2018 , 116, 1-6	35
1465	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. 2018 , 4, 351-357	357
1464	The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer. 2018 , 142, 2344-2354	35
1463	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. 2018 , 33, 62-68	4
1462	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ in Advanced Solid Tumors. 2018 , 24, 1287-1295	195
1461	The Basics of Cancer Immunotherapy. 2018 ,	2
1460	Significance of Immune Checkpoints in Lung Cancer. 2018 , 59-77	
1459	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. 2018 , 360, k793	262
1458	Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab. 2018 , 24, 3857-3866	97

1457	CIMAvax-EGF: Toward long-term survival of advanced NSCLC. 2018 , 45, 34-40	10
1456	Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. 2018 , 18, 302	13
1455	Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. 2018 , 18, 395	12
1454	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. 2018 , 19, 233	33
1453	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. 2018 , 6, 26	89
1452	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. 2018 , 13, 1128-1137	84
1451	The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. 2018 , 6, 15	13
1450	Therapeutic antibodies: A new era in the treatment of respiratory diseases?. 2018 , 189, 149-172	18
1449	Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. 2018 , 31, 1381-1390	34
1448	CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. 2018 , 38, 1063-1078	164
1447	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. 2018 , 13, 1037-1042	58
1446	Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer. 2018 , 7, e1457600	14
1445	Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature. 2018 , 26, 2945-2953	40
1444	Checkpoint Inhibitors in the Treatment of Breast Cancer. 2018 , 20, 51	10
1443	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. 2018 , 500, 621-625	34
1442	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. 2018 , 1461-1505	
1441	Recent advances in the management of lung cancer. 2018 , 18, s41-s46	110
1440	Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. 2018 , 101, 624-629	67

1439	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. 2018 , 13, 831-839	57
1438	Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma. 2018 , 19, e551-e558	7
1437	Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. 2018 , 80, 100-102	5
1436	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. 2018 , 4, e180013	834
1435	Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. 2018 , 54, 346-348	4
1434	WITHDRAWN: Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns. 2018 ,	
1433	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. 2018 , 15, 17-20	7
1432	Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC. 2018 , 42, 363-369	20
1431	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. 2018 , 11, 17562864187596183	
1430	Pseudoprogression and hyperprogression after checkpoint blockade. 2018 , 58, 125-135	89
1429	[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists]. 2018 , 38, 110-125	14
1428	Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?. 2018 , 13, 475-477	4
1427	Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer. 2018 , 13, 926-937	17
1426	Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. 2018 , 4, 1-7	5
1425	Regulation and Function of the PD-L1 Checkpoint. 2018 , 48, 434-452	783
1424	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. 2018 , 119, 71-77	31
1423	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. 2018 , 19, 331-339	13
1422	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. 2018 , 22, 453-461	8

1421	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. 2018 , 24, 2804-2811	167
1420	Programmed death ligand 1 expression and CD8 tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer. 2018 , 498, 751-757	41
1419	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. 2018 , 94, 179-186	53
1418	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. 2018 , 23, 936-942	46
1417	Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?. 2018 , 95, 127-129	4
1416	Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab. 2018 , 13, e39-e40	14
1415	Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. 2018 , 19, e405-e415	36
1414	Targeting immune checkpoints in non small cell lung cancer. 2018 , 40, 46-50	36
1413	Genomic Testing in Lung Cancer: Past, Present, and Future. 2018 , 16, 323-334	17
1412	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 2018 , 19, 521-536	315
1411	Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. 2018 , 19, 315-322	25
1410	Emerging growth factor receptor antagonists for ovarian cancer treatment. 2018 , 23, 1-16	1
1409	Bilateral Anterior Uveitis Associated with Nivolumab Therapy. 2018 , 26, 283-285	28
1408	Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. 2018 , 103, 318-331	16
1407	Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study. 2018 , 26, 489-494	31
1406	The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. 2018 , 8,	8
1405	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. 2018 , 19, 42-50	5
1404	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. 2018 , 19, 1-11	34

1403	Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. 2018 , 155, 382-392.e1	20
1402	Toxicity profiles of immunotherapy. 2018 , 181, 91-100	40
1401	Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro. 2018 , 282, 154-165	11
1400	Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency. 2018 , 28, 59-68	21
1399	Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy. 2018 , 126, 122-128	45
1398	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. 2018 , 20, 95-109	32
1397	Toxicity adjustment in the ESMO-MCBS: a gestalt approach?. 2018 , 29, 520-521	2
1396	Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer. 2018 , 40, 9-16	69
1395	Low PD-1 Expression in Cytotoxic CD8 Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value. 2018 , 24, 407-419	124
1394	Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. 2018 , 142, 1277-1284	55
1393	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. 2018 , 124, 271-277	173
1392	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. 2018 , 4, 173-182	467
1391	Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. 2018 , 4, 374-378	517
1390	Synthesis and Biologic Evaluation of a Novel F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression. 2018 , 59, 529-535	106
1389	The application and mechanism of PD pathway blockade for cancer therapy. 2018 , 94, 53-60	9
1388	PD-L1 in breast cancer: comparative analysis of 3 different antibodies. 2018 , 72, 28-34	32
1387	Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer. 2018 , 418-433.e6	
1386	Maintenance Chemotherapy for Nonsmall Cell Lung Cancer. 2018 , 448-465.e4	

1385	Immunotherapy and Lung Cancer. 2018 , 501-511.e3	2
1384	Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. 2018 , 72, 449-459	54
1383	Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. 2017 , 7, e1375642	52
1382	Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. 2018 , 31, 101-110	21
1381	Programmed death ligand 1-associated antitumor immunity in early-stage non-small cell lung cancer: Expression of major histocompatibility complex I as a prerequisite. 2018 , 155, 393-394	
1380	Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II Study. 2018 , 19, 157-162	9
1379	Prognostic value of PD-L1 expression in combination with CD8 TILs density in patients with surgically resected non-small cell lung cancer. 2018 , 7, 32-45	31
1378	Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. 2018 , 18, 63-70	89
1377	Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer. 2018 , 57, 2307-2313	28
1376	Durvalumab in non-small-cell lung cancer patients: current developments. 2018 , 14, 205-222	7
1375	Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. 2018 , 10, 93-105	72
1374	Lektion gelernt? Die molekularen Grundlagen von Kinase-gerichteten Therapien und Wirkstoffresistenz im nicht-kleinzelligen Lungenkrebs. 2018 , 130, 2329-2335	1
1373	Molecular Diagnosis and Targeting for Lung Cancer. 2018 , 1-32	
1372	Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. 2018 , 10, 315-324	39
1371	Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. 2018 ,	0
1370	Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer. 2018 , 168, 337-348	3
1369	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. 2018 , 6, 79-86	46
1368	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. 2018 , 27, 55-70	3

1367	High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer. 2018 , 67, 495-505	10
1366	Current and future immunotherapies for thyroid cancer. 2018 , 18, 149-159	37
1365	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. 2018 , 52, 53-65	39
1364	Product review on the Anti-PD-L1 antibody atezolizumab. 2018 , 14, 269-276	22
1363	Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates. 2018 , 32, 461-468	15
1362	Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. 2018 , 37, 687-709	6
1361	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. 2018 , 67, 459-470	82
1360	Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. 2018 , 115, 84-88	29
1359	Immune checkpoint inhibitors in advanced non-small cell lung cancer. 2018 , 124, 248-261	65
1358	Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. 2018 , 12, 229-235	37
1357	Drug development in the era of precision medicine. 2018 , 17, 183-196	176
1356	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. 2018 , 24, 1562-1573	93
1355	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. 2018 , 67, 471-481	4
1354	PD-L1. 2018 , 71, 189-194	129
1353	Immunotherapeutic Biomarkers and Selection Strategies. 2018 , 69-114	
1352	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. 2018 , 7, e1396403	34
1351	The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. 2018 , 19, 120-129	48
1350	Early Phase Cancer Immunotherapy. 2018 ,	1

1349 Thoracic Immunotherapy. **2018**, 281-305

1348 Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. **2018**, 243-280

1347 Immune checkpoint inhibitors: new strategies to checkmate cancer. **2018**, 191, 133-148 48

1346 Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. **2018**, 136, 453-461 20

1345 PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. **2018**, 62, 39-49 67

1344 Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. **2018**, 115, 12-20 98

1343 Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. **2018**, 52, 166-177 8

1342 PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. **2018**, 22, 1-10 89

1341 Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis. **2018**, 12, 1809-1819 18

1340 Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. **2018**, 24, 1260-1270 164

1339 Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. **2018**, 6, 59-68 15

1338 Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer. **2018**, 19, e177-e184 5

1337 Immunotherapy for thoracic malignancies. **2018**, 34, 54-64

1336 New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. **2018**, 106, 89-100 11

1335 Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. **2018**, 7, 404-415 46

1334 The role of immune checkpoint inhibitors in non-small cell lung cancer. **2018**, 2, 35-35

1333 "My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now?" Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. **2018**, 38, 696-707 5

1332 Treatment of Advanced Non-Small-Cell Lung Cancer: From Chemotherapy to Chemoimmunotherapy. **2018**, 14, 537-538 6

1331	Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?. 2018 , 36, 631-632	106
1330	Intensive care in cancer patients in the age of the multidisciplinary approach of cancer treatments: The radiotherapy perspective. 2018 , 42, 569-570	
1329	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. 2018 , 9, 610-617	131
1328	Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. 2018 , 38, 400-414	37
1327	Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. 2018 , 36, 1905-1912	189
1326	A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis. 2018 , 11, 172	
1325	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. 2018 , 4, 1-6	15
1324	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. 2018 , 36, 1675-1684	381
1323	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. 2018 , 36, 633-641	730
1322	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. 2018 , 36, 1207-1217	17
1321	Patterns of Response and Progression to Immunotherapy. 2018 , 38, 169-178	128
1320	Immune Checkpoint Inhibitors in the Management of Lung Cancer. 2018 , 38, 682-695	17
1319	Tumor Mutation Burden: Is It Ready for the Clinic?. 2018 , 36, 2978-2979	11
1318	Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer. 2018 , 14, 23-31	29
1317	Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?. 2018 , 10, S3203-S3206	4
1316	Lung cancer in never smokers-the East Asian experience. 2018 , 7, 450-463	47
1315	Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. 2018 , 7, 668-677	40
1314	PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. 2018 , 15, 434-442	16

1313	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?. 2018 , 7, 682-690	17
1312	Immunotherapy in treatment naïve advanced non-small cell lung cancer. 2018 , 10, S412-S421	8
1311	Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer. 2018 , 10, 1205-1206	1
1310	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. 2018 , 10, S3162-S3165	
1309	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. 2018 , 7, 647-660	50
1308	Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?. 2018 , 10, S3241-S3243	1
1307	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. 2018 , 10, S4034-S4037	3
1306	Role of immune checkpoint blockers in patients with mutation. 2018 , 7, S385-S387	2
1305	Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer. 2018 , 7, S377-S380	3
1304	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). 2018 , 9, 17554-17563	16
1303	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. 2018 , 10, 21-24	1
1302	Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. 2018 , 10, 25-29	3
1301	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. 2018 , 10, 219-227	4
1300	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. 2018 , 10, S1516-S1533	36
1299	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. 2018 , 10, S1461-S1467	15
1298	Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. 2018 , 10, S451-S459	22
1297	Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. 2018 , 10, 816-824	5
1296	Do immune checkpoint inhibitors need new studies methodology?. 2018 , 10, S1564-S1580	35

1295	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). 2018 , 10, S422-S432	6
1294	Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios. 2018 , 10, S1494-S1502	11
1293	Oncogene-addicted non-small cell lung cancer and immunotherapy. 2018 , 10, S1547-S1555	24
1292	Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?. 2018 , 10, 1276-1279	3
1291	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. 2018 , 10, S995-S998	1
1290	The evolving understanding of immunoediting and the clinical impact of immune escape. 2018 , 10, 1248-1252	8
1289	Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. 2018 , 10, S1534-S1546	5
1288	Immunotherapy in the Asiatic population: any differences from Caucasian population?. 2018 , 10, S1482-S1493	23
1287	Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics. 2018 , 7, S39-S45	5
1286	Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution. 2018 , 7, S91-S94	14
1285	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. 2018 , 7, 464-486	8
1284	Reirradiation for locoregionally recurrent non-small cell lung cancer. 2018 , 10, S2522-S2536	17
1283	Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189. 2018 , 10, 5186-5189	0
1282	Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching. 2018 , 10, S2195-S2197	3
1281	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. 2018 , 10, S433-S450	13
1280	Identifying and managing the adverse effects of immune checkpoint blockade. 2018 , 10, S480-S489	55
1279	VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy. 2018 , 10, 6378-6382	6
1278	PD-L1 immunohistochemistry in patients with non-small cell lung cancer. 2018 , 10, S2127-S2129	4

1277	Harmonization study of antibodies and platforms for programmed death ligand 1 immunostaining in non-small cell lung cancer: does shuffling couples settle the troubles?. 2018 , 10, S2124-S2126	1
1276	Atezolizumab in non-squamous non-small cell lung cancer. 2018 , 10, S3155-S3159	4
1275	Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. 2019 , 10, 161-165	9
1274	Pembrolizumab in patients with thymic carcinoma: a cautionary tale. 2018 , 2, 55-55	1
1273	Combining immunotherapy with radiation therapy in thoracic oncology. 2018 , 10, S2492-S2507	10
1272	Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. 2018 , 10, S4082-S4084	0
1271	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. 2018 , 7, S198-S201	3
1270	PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. 2018 , 7, S283-S286	1
1269	Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma: A case report. 2018 , 97, e13427	1
1268	Management of Advanced Non-Small Cell Lung Cancer. 2018 , 99-115	1
1267	Histology versus cytology: PD-L1 testing in non-small cell lung cancer. 2018 , 7, S225-S227	4
1266	Quality of life for non-small cell lung cancer patients in the age of immunotherapy. 2018 , 7, S149-S152	10
1265	Căcer de pulmă. 2018 , 12, 3803-3811	
1264	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. 2018 , 7, S290-S293	0
1263	Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. 2018 , 7, S95-S99	7
1262	The clinical utility of tumor mutational burden in non-small cell lung cancer. 2018 , 7, 639-646	61
1261	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. 2018 , 7, LMT07	1
1260	ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report. 2019 , 17, 488-491	2

1259	Combining immunotherapy and radiotherapy in lung cancer. 2018 , 10, S1447-S1460	43
1258	Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. 2019 , 17, 1019-1029	4
1257	Immunotherapy in Advanced Lung Cancer Treatment. 2018 ,	
1256	Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns. 2018 , 105 Suppl 1, S80-S91	0
1255	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. 2018 , 14, 529-535	17
1254	The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. 2018 , 9, 7942-7948	18
1253	The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. 2018 , 9, 4239-4248	10
1252	Repeated Abscopal Effect With Radiotherapy and Programmed Death 1 Blockade in Mismatch Repair-Deficient Endometrial Cancer.. 2018 , 2, 1-6	3
1251	Treatment Options in Oncology. 2018 , 2, 1-10	12
1250	Nivolumab Induced Toxicity Presenting As Pneumonitis- A Case Report. 2018 , 08,	
1249	Complexity and uncertainty in the critical care of cancer patients in the era of immunotherapy and targeted therapies. 2018 , 42, 570-571	
1248	Immunotherapy and new frontiers in the treatment of lung cancer. 2018 , 2, 77-77	
1247	Der Einsatz von Checkpoint-Hemmern beim Lungenkarzinom wird breiter. 2018 , 10, 34-42	
1246	[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs]. 2018 , 105, 1202-1208	1
1245	Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report. 2018 , 97, e13739	2
1244	Immuntherapien mit Checkpoint-Inhibitoren – Eine Übersicht. 2018 , 50, 120-123	
1243	Medikamentöse Therapie des metastasierten oder rezidierten mutationsnegativen NSCLC. 2018 , 24, 1003-1008	0
1242	Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. 2018 , 13, e0206370	37

1241	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. 2018 , 363, k4226	191
1240	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. 2018 , 18, 1082	29
1239	Interferon- β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells. 2018 , 507, 330-336	31
1238	Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer. 2018 , 11, 278-287	13
1237	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. 2018 , 10, 1303-1313	1
1236	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. 2018 , 6, 126	17
1235	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. 2018 , 11, 7529-7542	20
1234	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. 2018 , 17, 1197-1209	8
1233	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. 2018 , 6, 128	138
1232	Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. 2018 , 9, 85-90	12
1231	Lung cancer, elderly and immune checkpoint inhibitors. 2018 , 10, S1474-S1481	17
1230	Combination of PD-1 blockade and RetroNectin-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. 2018 , 10, 1315-1323	3
1229	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. 2018 , 19, 1579-1589	395
1228	Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. 2018 , 18, 1105	40
1227	Functionally impaired follicular helper T cells induce regulatory B cells and CD14 human leukocyte antigen-DR cell differentiation in non-small cell lung cancer. 2018 , 109, 3751-3761	16
1226	FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. 2018 , 45, 220-225	48
1225	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. 2018 , 6, 114	29
1224	Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. 2018 , 25, e373-e384	61

1223	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. 2018 , 9, 4664	202
1222	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. 2018 , 19, 2055-2062	18
1221	Lessons in practicing cancer genomics and precision medicine. 2018 , 3, 287-298	
1220	Intensive care in cancer patients in the age of the multidisciplinary approach of cancer treatments: The radiotherapy perspective. 2018 , 42, 569-570	2
1219	A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the OncoPrint Tumor Mutation Load Assay. 2018 , 7, 616-630	30
1218	The promise of immunotherapy in genitourinary malignancies. 2018 , 1, 97-101	2
1217	Actualit�� et perspectives concernant lâ��immunoth��rapie en oncologie thoracique. 2018 , 105 Suppl 1, S16-S23	
1216	Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. 2018 , 11, 8623-8632	8
1215	Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring S310Y mutation: a case report. 2018 , 11, 8705-8710	5
1214	Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. 2018 , 9, 5361	145
1213	Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. 2018 , 11, 8565-8573	7
1212	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. 2018 , 9, 1430	54
1211	Gene code : from molecular basis toward cancer immunotherapy. 2018 , 10, 1758835918815598	20
1210	Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. 2018 , 10, 4689-4693	36
1209	Overview of Basic Immunology and Translational Relevance for Clinical Investigators. 2018 , 995, 1-41	2
1208	Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. 2018 , 995, 65-95	38
1207	Immune-Related Adverse Events: Pneumonitis. 2018 , 995, 131-149	14
1206	Organoid Modeling of the Tumor Immune Microenvironment. 2018 , 175, 1972-1988.e16	478

1205	Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?. 2018 , 7, S275-S279	22
1204	Chimiothérapie de première ligne incluant le traitement de maintenance et les anti-angiogéniques dans les CBNPC avancés en l'absence d'addiction oncogénique. 2018 , 10, 369-379	
1203	Traitements de deuxième ligne et ultérieure des cancers broncho-pulmonaires non à petites cellules sans addiction oncogénique. 2018 , 10, 385-390	
1202	Prise en charge thérapeutique des cancers bronchiques non à petites cellules de stades avancés mutés pour l'EGFR. 2018 , 10, 425-439	0
1201	Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. 2018 , 9, 35439-35447	2
1200	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. 2018 , 8, 563	22
1199	[An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function]. 2018 , 55, 679-685	
1198	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. 2018 , 7,	38
1197	Immunotherapy. 2018 ,	3
1196	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. 2018 , 6, 141	132
1195	Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263. 2018 , 38, 6891-6895	14
1194	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. 2018 , 9, 4325-4333	12
1193	Prime time for immunotherapy in advanced urothelial cancer. 2018 , 14 Suppl 5, 24-32	2
1192	Myosites induites par les Inhibiteurs de Checkpoint Immunitaires: une nouvelle myopathie auto-immune associée à une atteinte myocardique de mauvais pronostic. 2018 , 39, A75-A76	
1191	Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. 2018 , 38, 6771-6782	17
1190	Les essais cliniques princeps en immuno-oncologie dans les cancers broncho-pulmonaires. 2018 , 10, 469-480	
1189	Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study. 2019 , 10, 137-143	24
1188	Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report. 2018 , 9, 2145	25

1187 Response. **2018**, 154, 993-994

1186 The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma. **2018**, 7, 324-332 8

1185 Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients. **2018**, 125, 230-237 5

1184 Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. **2018**, 11, 6189-6196 35

1183 A review of guidelines for lung cancer. **2018**, 10, S1556-S1563 41

1182 Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. **2018**, 154, 1416-1423 111

1181 Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. **2018**, 9, 1500-1508 13

1180 [Comparison of Chemical Behavior of Original and Generic Docetaxel Formulations as Non-alcoholic Preparations: Discussion about Diluent Solvents for Docetaxel]. **2018**, 138, 973-984 2

1179 Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy. **2018**, 118, 1170-1177 6

1178 Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. **2018**, 8, 351 56

1177 Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. **2018**, 125, 150-156 89

1176 Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. **2018**, 12, 2857-2873 7

1175 Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression. **2018**, 11, 5601-5605 3

1174 Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. **2018**, 19, 1468-1479 237

1173 Avelumab in non-small-cell lung cancer. **2018**, 19, 1423-1424 5

1172 The intracellular signalosome of PD-L1 in cancer cells. **2018**, 3, 26 108

1171 Immuntherapien beim fortgeschrittenen NSCLC. **2018**, 39, 371-384

1170 Pulmonary Toxicities of Anticancer Treatment. **2018**, 201-215

1169	Pigtail Catheter Drainage Can Be Considered as the Initial Treatment Option for Patients With Pneumothorax: Not Yet Determined. 2018 , 154, 994-995	
1168	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. 2018 , 11, 5973-5989	59
1167	Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. 2018 , 125, 212-217	63
1166	Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma. 2018 , 38, 6003-6008	
1165	Pembrolizumab for the treatment of gastric cancer. 2018 , 18, 1177-1187	12
1164	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018 , 29, iv192-iv237	897
1163	Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). 2018 , 18, 946	23
1162	Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. 2018 , 379, 2040-2051	1582
1161	Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies. 2018 , 18, 1205-1217	7
1160	Prognostic impact of the tumor immune microenvironment in synovial sarcoma. 2018 , 109, 3043-3054	32
1159	Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients. 2018 ,	0
1158	Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy. 2018 , 13, 76-84	5
1157	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. 2018 , 25, 374-386	10
1156	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. 2018 , 11, 5879-5883	7
1155	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. 2018 , 13, 795-800	14
1154	Liver Toxicity with Cancer Checkpoint Inhibitor Therapy. 2018 , 38, 366-378	24
1153	[Predictive value of PD-L1 'diagnostics']. 2018 , 39, 498-519	35
1152	Effect of anesthetic methods on postoperative CD3, CD4 and CD4CD25 in patients with lung cancer undergoing radical operation. 2018 , 16, 6547-6551	3

1151	ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). 2018 , 124, 4667-4675	7
1150	Toxicity of radiation and immunotherapy combinations. 2018 , 3, 506-511	22
1149	Next generation immune-checkpoints for cancer therapy. 2018 , 10, S1581-S1601	38
1148	2018 Nobel Prize in physiology or medicine. 2018 , 7, e1041	23
1147	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. 2018 , 13, 1906-1918	50
1146	[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]. 2018 , 74, 327-338	2
1145	Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. 2018 , 2018, 3820956	14
1144	Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. 2018 , 138, 743-745	91
1143	Durvalumab in NSCLC: latest evidence and clinical potential. 2018 , 10, 1758835918804151	16
1142	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. 2018 , 13, 1733-1742	79
1141	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. 2018 , 13, 1884-1896	47
1140	Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. 2018 , 29, 2092-2097	36
1139	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. 2018 , 32, 1541-1550	4
1138	Aging, immune senescence, and immunotherapy: A comprehensive review. 2018 , 45, 187-200	40
1137	Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. 2018 , 3, e000406	45
1136	The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung Cancer. 2018 , 2018, 5068701	10
1135	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment. 2018 , 6, 106	85
1134	Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. 2018 , 11, 6287-6294	8

1133	Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms. 2018 , 9, 3489-3499	10
1132	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. 2018 , 119, 950-960	83
1131	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. 2018 , 9, 8706-8715	52
1130	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. 2018 , 71, 47-58	28
1129	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. 2018 , 23, 283-299	21
1128	TIM-3 expression in breast cancer. 2018 , 7, e1502128	34
1127	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. 2018 , 132, 125-129	14
1126	Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy. 2018 , 35, 591-598	1
1125	[Molecular predictors in immune oncology]. 2018 , 39, 546-555	2
1124	Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer. 2018 , 9, 1476-1482	5
1123	Foundations of Respiratory Medicine. 2018 ,	
1122	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. 2018 , 12, 1753466618794133	27
1121	Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel-Aviv tertiary medical center: Facing the reality. 2018 , 9, 419-422	3
1120	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. 2018 , 4, 1543-1552	380
1119	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. 2018 , 103, 7-16	32
1118	New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey. 2018 , 4,	2
1117	Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. 2018 , 102, 527-535	27
1116	Combinations of Bevacizumab With Cancer Immunotherapy. 2018 , 24, 193-204	89

1115	The hallmarks of successful anticancer immunotherapy. 2018 , 10,	260
1114	Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients. 2018 , 25, 3755-3763	7
1113	Pembrolizumab for the first-line treatment of non-small cell lung cancer. 2018 , 18, 1015-1021	15
1112	Profiling targetable immune checkpoints in osteosarcoma. 2018 , 7, e1475873	19
1111	Radiological Features of IDO1/PDL1 Lung Adenocarcinoma: A Retrospective Single-institution Study. 2018 , 38, 5295-5303	2
1110	Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. 2018 , 32, 1155-1160	3
1109	Expert opinions on adrenal complications in immunotherapy. 2018 , 79, 539-544	9
1108	PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma. 2018 , 19, e957-e963	17
1107	Impact of PD-L1, transforming growth factor- β expression and tumor-infiltrating CD8 T cells on clinical outcome of patients with advanced thymic epithelial tumors. 2018 , 9, 1341-1353	10
1106	sLAG-3 in non-small-cell lung cancer patients' serum. 2018 , 11, 4781-4784	12
1105	A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma. 2018 , 143, 2592-2601	14
1104	Cure in metastatic breast cancer. 2018 , 11, 172-179	17
1103	Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. 2018 , 97, e11936	56
1102	Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. 2018 , 13, e0203070	6
1101	Immune checkpoint inhibitors and cardiovascular toxicity. 2018 , 19, e447-e458	221
1100	EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?. 2018 , 13, 1245-1247	1
1099	PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth". 2018 , 13, 1239-1241	
1098	Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. 2018 , 124, 248-254	40

1097	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. 2018 , 2018, 6984948	100
1096	Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. 2018 , 78, 6486-6496	104
1095	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. 2018 , 10, 6636-6652	25
1094	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. 2018 , 32, 527-542	9
1093	Role of Imaging in Early-Phase Trials. 2018 , 129-149	1
1092	Clinical Trial Design in Immuno-Oncology. 2018 , 151-173	
1091	PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. 2018 , 13, 1113-1120	91
1090	Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study. 2018 , 19, e667-e673	9
1089	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. 2018 , 8, 822-835	648
1088	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. 2018 , 56, 460-472	13
1087	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. 2018 , 430, 2014-2029	30
1086	Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. 2018 , 13, 978-986	60
1085	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. 2018 , 13, 1146-1155	57
1084	Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells. 2018 , 13, 1324-1337	18
1083	Emerging biomarkers for immune checkpoint inhibition in lung cancer. 2018 , 52, 269-277	54
1082	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. 2018 , 10, 1758835918772810	11
1081	Factor XIIIa-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. 2018 , 9, 1988	39
1080	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. 2018 , 23, 1171-1177	19

1079	Menace Elbow: Disseminated Nocardiosis. 2018 , 131, 1307-1309	2
1078	Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient. 2018 , 19, e591-e596	2
1077	Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer. 2018 , 13, 741-744	4
1076	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. 2018 , 68, 69-79	36
1075	Development of an Enzyme-Linked Immune Sorbent Assay to Measure Nivolumab and Pembrolizumab Serum Concentrations. 2018 , 40, 596-601	10
1074	Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer. 2018 , 38, 3587-3592	5
1073	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. 2018 , 38, 3689-3697	23
1072	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. 2018 , 144, 1601-1611	6
1071	Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. 2018 , 19, 441-449.e4	42
1070	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. 2018 , 19, 426-434.e1	64
1069	The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. 2018 , 198, 24-38	11
1068	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. 2018 , 19, 737-746	353
1067	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. 2018 , 37, 4639-4661	133
1066	Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data. 2018 , 28, 1196-1202	7
1065	Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. 2018 , 13, 1156-1170	134
1064	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. 2018 , 38, 3789-3796	39
1063	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. 2018 , 122, 234-242	15
1062	Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. 2018 , 2018, 1027323	26

1061	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. 2018 , 23, 1358-1365	139
1060	Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. 2018 , 129, 27-39	28
1059	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. 2018 , 2018, 2783917	2
1058	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. 2018 , 2018, 8202971	13
1057	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. 2018 , 13, e0198634	18
1056	T Lymphocyte-Based Cancer Immunotherapeutics. 2018 , 341, 201-276	12
1055	Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. 2018 , 8, 9686	0
1054	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. 2018 , 29, 1727-1740	12
1053	Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas. 2018 , 29, 550-557	30
1052	The changing scenario of 1 line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. 2018 , 130, 1-12	16
1051	Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. 2018 , 32, 887-891	6
1050	Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine. 2018 , 19, 43	8
1049	Real-World Pseudoprogression: an Uncommon Phenomenon. 2018 , 13, 880-882	9
1048	Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells. 2018 , 80, 170-178	30
1047	Lipid Accumulation in Peripheral Blood Dendritic Cells and Anticancer Immunity in Patients with Lung Cancer. 2018 , 2018, 5708239	9
1046	Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications. 2018 , 82, 171-183	12
1045	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. 2018 , 128, 19-29	7
1044	Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. 2018 , 33, 94-104	6

1043	HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?. 2018 , 13, 874-876	4
1042	Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer. 2018 , 69, 143-151	16
1041	Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. 2018 , 67, 1365-1370	12
1040	Durvalumab for the treatment of non-small cell lung cancer. 2018 , 12, 627-639	16
1039	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes. 2018 , 1, e180416	30
1038	Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis. 2018 , 35, 1035-1048	1
1037	DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. 2018 , 9, 901-903	2
1036	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). 2018 , 40, 173-189	22
1035	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. 2018 , 13, 1569-1576	140
1034	Latest development of liquid biopsy. 2018 , 10, S1645-S1651	38
1033	Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. 2018 , 8, 278	7
1032	Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer. 2018 , 25, S94-S102	28
1031	Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. 2018 , 25, S68-S76	6
1030	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. 2018 , 81, 29-41	12
1029	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. 2018 , 2, pky021	73
1028	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. 2018 , 10,	24
1027	KRAS-Mutant non-small cell lung cancer: From biology to therapy. 2018 , 124, 53-64	133
1026	A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. 2018 , 18, 620	6

1025	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. 2018 , 12, 1645-1657	13
1024	Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer. 2018 , 38, 4637-4644	19
1023	Immune Checkpoint Inhibitor Toxicity. 2018 , 20, 72	63
1022	PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. 2018 , 40, 331-338	5
1021	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. 2018 , 18, 937-945	10
1020	Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies. 2018 , 129, 133-145	18
1019	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. 2018 , 9, 1813-1820	34
1018	A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. 2018 , 9, 1200-1206	22
1017	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. 2018 , 13, 47	24
1016	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. 2018 , 10, 931-940	8
1015	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. 2018 , 10, 1758835918786228	28
1014	An Update on Immunotherapy for Solid Tumors: A Review. 2018 , 25, 3404-3412	43
1013	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. 2018 , 11, 4051-4064	10
1012	Adaptive expansion of biomarker populations in phase 3 clinical trials. 2018 , 71, 181-185	6
1011	Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis. 2018 , 13, e0199575	7
1010	Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years. 2018 , 15, 119-124	4
1009	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. 2018 , 101, 201-209	36
1008	Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. 2018 , 10, 887-897	7

1007	Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. 2018 , 9, 14	201
1006	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. 2018 , 9, 374	35
1005	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. 2018 , 9, 1474	126
1004	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. 2018 , 8, 86	529
1003	Editorial: Controversies in the Local Management of Lung Cancer. 2018 , 8, 233	0
1002	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. 2018 , 6, 65	70
1001	Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. 2018 , 13, 509-515	21
1000	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. 2018 , 109, 2539-2548	24
999	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. 2018 , 6, 46	86
998	Oncogene addicted non-small-cell lung cancer: current standard and hot topics. 2018 , 14, 3-17	17
997	New options on the horizon for nononcogene addicted non-small-cell lung cancer. 2018 , 14, 19-28	1
996	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. 2018 , 10,	37
995	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. 2018 , 10,	33
994	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. 2018 , 122, 160-164	5
993	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. 2018 , 62, 29-39	496
992	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. 2018 , 14, 2415-2431	19
991	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. 2018 , 7, e1480301	32
990	BRAF Mutations-A Good News Story for Immune Checkpoint Inhibitors in Oncogene-Addicted NSCLC?. 2018 , 13, 1055-1057	0

989	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. 2018 , 7,	8
988	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. 2018 , 7,	36
987	Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine. 2018 , 7,	30
986	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. 2018 , 16, 807-821	314
985	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. 2018 , 10, 797-805	17
984	Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis. 2018 , 15, 5671-5679	2
983	Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. 2018 , 100, 126-134	65
982	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). 2018 , 6, 69	10
981	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. 2018 , 65, e27313	7
980	Expected advances in human fertility treatments and their likely translational consequences. 2018 , 16, 149	4
979	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). 2018 , 6, 75	107
978	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. 2018 ,	5
977	Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives. 2018 , 11, 112-115	2
976	Management of adverse events related to checkpoint inhibition therapy. 2018 , 11, 132-137	17
975	Complexity and uncertainty in the critical care of cancer patients in the era of immunotherapy and targeted therapies. 2018 , 42, 570-571	3
974	Lung Cancer: Advances and Insights in Diagnosis, Treatment, and Palliation. 2018 , 198, 667-669	2
973	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. 2018 , 14, 41-60	7
972	Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. 2018 , 101, 1141-1148	44

971	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. 2018 , 39, 1693-1698	24
970	Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. 2018 , 144, 1851-1859	39
969	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. 2018 , 19,	12
968	Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes. 2018 , 14, 204-216	49
967	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. 2018 , 20, 696-704	23
966	Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?. 2018 , 16, 24	8
965	Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. 2018 , 6, 22	29
964	PD-L1 Expression in a Non-Small Cell Lung Cancer Specimen Obtained by EBUS-TBNA. 2018 , 54, 290-292	1
963	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. 2018 , 11, 15	93
962	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. 2018 , 6, 8	606
961	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study. 2018 , 18, 333	7
960	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. 2018 , 8, 530-538	27
959	Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. 2018 , 7, 11	25
958	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. 2018 , 19, 851-864	4
957	Combination Immunotherapy in Non-small Cell Lung Cancer. 2018 , 20, 55	20
956	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. 2018 , 11, 104	164
955	Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer. 2018 , 130, 36-43	0
954	Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer. 2018 , 9, 7672-7683	10

953	Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. 2018 , 9, 16512-16520	50
952	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). 2018 , 6, 144	17
951	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin'. 2018 , 19, 461-463	1
950	Treatment of advanced non-small cell lung cancer in the elderly. 2018 , 12, 783-792	4
949	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). 2018 , 124, 117-124	19
948	Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. 2018 , 24, 6212-6222	95
947	Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. 2018 , 9, 129-134	9
946	Current and future developments of immunotherapy in lung cancer. 2018 , 11, 122-131	0
945	A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. 2018 , 9, 3196	87
944	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. 2018 , 3, e000332	32
943	Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?. 2018 , 3, e000421	8
942	Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview. 2018 , 25, S77-S85	7
941	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. 2018 , 144, 2245-2261	16
940	Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. 2018 , 124, 179-188	35
939	Intensive care in cancer patients in the age of immunotherapy and molecular therapies: Commitment of the SEOM-SEMICYUC. 2018 , 42, 363-369	
938	Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. 2018 , 54, 346-348	1
937	Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. 2018 , 52,	13
936	Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. 2018 , 13, e0202725	11

935	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. 2018 , 125, 273-281	40
934	Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. 2018 , 25, e324-e334	38
933	Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients. 2018 , 24, 6345-6354	31
932	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. 2018 , 19, 46	9
931	Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. 2018 , 503, 2764-2769	6
930	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. 2018 , 9, 1614-1622	12
929	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. 2018 , 35, 819-834	7
928	Review of checkpoint immunotherapy for the management of non-small cell lung cancer. 2018 , 7, 63-75	36
927	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. 2018 , 6,	5
926	Efficacy of icotinib in advanced lung squamous cell carcinoma. 2018 , 7, 4456-4466	8
925	Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis. 2018 , 8, 11738	16
924	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. 2018 , 6, 771-781	107
923	Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. 2018 , 11, 4233-4246	12
922	First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. 2018 , 123, 166-171	20
921	The Cancer Omics Atlas: an integrative resource for cancer omics annotations. 2018 , 11, 63	12
920	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. 2018 , 10, 2475-2488	11
919	The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. 2018 , 12, 981-986	25
918	Patient performance status and cancer immunotherapy efficacy: a meta-analysis. 2018 , 35, 132	32

917	Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer. 2018 , 9, 1291-1299	33
916	Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens. 2018 , 154, 827-837	39
915	Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF- κ B signaling. 2018 , 53, 1469-1480	41
914	Molecular imaging of T cell co-regulator factor B7-H3 with Zr-DS-5573a. 2018 , 8, 4199-4209	23
913	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. 2018 , 23, 991-997	61
912	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. 2018 , 378, 2288-2301	1695
911	Safety of combining radiotherapy with immune-checkpoint inhibition. 2018 , 15, 477-494	132
910	Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer. 2018 , 42, 1090-1094	17
909	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. 2018 , 41, 114-121	51
908	Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016. 2018 , 122, 138-145	16
907	Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. 2018 , 4, 1189-1197	39
906	Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. 2018 , 24, 5841-5849	97
905	PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists. 2018 , 42, 1384-1389	52
904	Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma. 2018 , 57, 3149-3152	1
903	Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. 2018 , 29, 1701-1709	11
902	Tissue and Blood Biomarkers in Lung Cancer: A Review. 2018 , 86, 1-21	48
901	Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. 2018 , 13, e0192227	55
900	The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. 2018 , 13, e0193018	46

899	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. 2018 , 93, 917-936	3
898	Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer. 2018 , 38, 3231-3242	13
897	Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. 2018 , 10, 681-694	25
896	Recent progress in therapeutic antibodies for cancer immunotherapy. 2018 , 44, 56-65	19
895	Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. 2018 , 4, 1138-1139	2
894	Observational study of chemotherapy-induced Clostridium difficile infection in patients with lung cancer. 2018 , 23, 1046-1051	1
893	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. 2018 , 23, 1052-1059	20
892	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. 2018 , 25, 1327-1339	69
891	Targeting EGFR in Lung Cancer: Current Standards and Developments. 2018 , 78, 893-911	40
890	Immunotherapy of Cancer. 2019 , 1033-1048.e1	1
889	Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. 2019 , 27, 97-107	9
888	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. 2019 , 105, 582-597	7
887	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. 2019 , 29, 29-39	29
886	Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. 2019 , 34, 108-117	85
885	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. 2019 , 22, 69-76	31
884	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. 2019 , 8, 155-171	14
883	Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy. 2019 , 25, 1275-1281	12
882	Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?. 2019 , 43, 43-53	1

881	Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015. 2019 , 37, 166-174	4
880	Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. 2019 , 59, 45-54	0
879	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. 2019 , 474, 485-495	2
878	Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. 2019 , 25, 957-966	28
877	Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. 2019 , 74, 269-275	9
876	Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non-Small Cell Lung Cancer. 2019 , 53, 324-331	
875	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. 2019 , 193, 20-30	35
874	Essential preanalytics in PD-L1 immunocytochemistry. 2019 , 74, 362-364	4
873	Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. 2019 , 20, 208-214.e2	53
872	Cancer immunotherapy-associated hypophysitis. 2019 , 15, 3159-3169	10
871	Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. 2019 , 464, 5-14	62
870	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. 2019 , 293, 15-29	23
869	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 2019 , 11, 873-879	10
868	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). 2019 , 20,	55
867	Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). 2019 , 37, 1266-1273	21
866	Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. 2019 , 4,	16
865	Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective. 2019 , 11, 199-219	1
864	Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. 2019 , 11, 521-534	12

863	Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib. 2019 , 11, 2664-2668	1
862	Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. 2019 , 8, 202-207	7
861	Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. 2019 , 41, 4036-4050	2
860	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. 2019 , 20, 1395-1408	149
859	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. 2019 , 19, 495-509	250
858	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. 2019 , 7, 221	2
857	Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. 2019 , 8, e1629261	28
856	Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. 2019 , 20, 442-450.e4	41
855	Dynamic changes in PD-L1 expression and CD8 T cell infiltration in non-small cell lung cancer following chemoradiation therapy. 2019 , 136, 30-36	13
854	Treatment of uncommon mutations in non-small cell lung cancer: new evidence and treatment. 2019 , 8, 302-316	45
853	Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. 2019 , 11, 993-1003	11
852	Therapeutic outcomes in non-small cell lung cancer with mutations: a single institution, retrospective cohort study. 2019 , 8, 258-267	7
851	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. 2019 , 39, 4265-4271	19
850	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. 2019 , 11, 1149-1160	8
849	Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. 2019 , 8,	46
848	Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies. 2019 , 20, 451-460.e5	4
847	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. 2019 , 233, 116713	25
846	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. 2019 , 15, 2423-2433	48

845	The estrogen pathway as a modulator of response to immunotherapy. 2019 , 11, 1161-1176	3
844	Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. 2019 , 136, 65-73	2
843	PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. 2019 , 15, 1667-1678	6
842	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. 2019 , 15, 2743-2757	5
841	Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience. 2019 , 11, 945-952	2
840	Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. 2019 , 125, 4019-4032	53
839	Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. 2019 , 94, 1623-1640	481
838	Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?. 2019 , 12, 505-512	2
837	Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer. 2019 , 20, 185	11
836	Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. 2019 , 11, 7707-7719	18
835	Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. 2019 , 28, 100879	6
834	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. 2019 , 65, 1228-1238	88
833	Novel Delivery Systems for Checkpoint Inhibitors. 2019 , 6,	15
832	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. 2019 , 36, 168-178.e4	124
831	Clinical genetic features and related survival implications in patients with surgically resected large-cell lung cancer. 2019 , 11, 5489-5499	2
830	Immuno-oncology for surgeons. 2019 , 106, 1273-1282	1
829	Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases. 2019 , 12, 5293-5298	15
828	Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. 2019 , 5, 1283-1290	124

827	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. 2019 , 5, 1276-1282	328
826	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. 2019 , 5, 1195-1204	224
825	Tumor Vasculatures: A New Target for Cancer Immunotherapy. 2019 , 40, 613-623	51
824	Pembrolizumab for the treatment of cervical cancer. 2019 , 19, 871-877	7
823	Rapid onset type 1 diabetes associated with the programmed cell death-1 inhibitor pembrolizumab. 2019 , 49, 930-931	0
822	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. 2019 , 142, 35-43	13
821	Opportunities of circulating tumor DNA in lung cancer. 2019 , 78, 31-41	12
820	MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance. 2019 , 2019, 7346492	15
819	Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. 2019 , 11, 1919-1928	10
818	Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. 2019 , 18, 161-168	0
817	Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis. 2019 , 8, 5033-5046	7
816	Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites. 2019 , 134, 202-209	20
815	Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. 2019 , 7, 172	5
814	Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. 2019 , 8,	17
813	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. 2019 , 12, 75	49
812	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. 2019 ,	
811	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. 2019 , 142, 16-25	17
810	A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer. 2019 , 12, 4955-4973	7

809	Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer. 2019 , 2019, 8014627	12
808	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. 2019 , 135, 188-195	99
807	Hepatotoxicity of immune check point inhibitors: Approach and management. 2019 , 51, 1074-1078	19
806	Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. 2019 , 2, e196879	97
805	Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. 2019 , 33, e22964	66
804	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. 2019 , 20, 1109-1123	113
803	Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging. 2019 , 16, 3469-3476	13
802	Challenges for real-time intraoperative diagnosis of high risk histology in lung adenocarcinoma: A necessity for sublobar resection. 2019 , 10, 1663-1668	10
801	Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. 2019 , 142, 9-15	10
800	Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice. 2019 , 97, 228-235	6
799	The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. 2019 , 65-84	
798	Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. 2019 , 10, 1798-1804	16
797	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. 2019 , 10, 1505	23
796	Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. 2019 , 10, 3717-3727	20
795	Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer. 2019 , 26, e300-e308	3
794	First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. 2019 , 7, 195	14
793	The biological functions and clinical applications of exosomes in lung cancer. 2019 , 76, 4613-4633	58
792	Clinical utility of ramucirumab in non-small-cell lung cancer. 2019 , 13, 133-137	3

791	Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report. 2019 , 12, 5389-5393	6
790	Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry. 2019 , 110, 2711-2721	17
789	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. 2019 , 21, 79	25
788	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer. 2019 , 10, 47-56	9
787	Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer. 2019 , 9, 478	8
786	Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. 2019 , 138, 75-79	6
785	Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front. 2019 , 38, 5921-5932	14
784	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. 2019 , 12, 67	26
783	Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. 2019 , 39, 931-938	13
782	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CANcer) trial. 2019 , 134, 210-217	8
781	Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. 2019 , 57, 451-459	35
780	Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer. 2019 , 74, 105709	5
779	Next-generation sequencing and biomarkers for gastric cancer: what is the future?. 2019 , 11, 1758835919848189	189
778	Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. 2019 , 10, 673	35
777	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). 2019 , 105, 3-14	6
776	Improving the prognosis for lung cancer patients. 2019 , 58, 1077-1078	7
775	Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. 2019 , 74, 105707	8
774	Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer. 2019 , 14, e141-e143	1

773	Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. 2019 , 14, 1619-1627	6
772	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. 2019 , 28, 369-386	13
771	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. 2019 , 32, 1772-1785	33
770	Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. 2019 , 20, 1609-1624	5
769	Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors. 2019 , 39, 3961-3965	19
768	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. 2019 , 11,	4
767	Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer. 2019 , 8,	35
766	Current Therapy and Development of Therapeutic Agents for Lung Cancer. 2022 , 100015	1
765	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).. 2022 , 166, 107-113	0
764	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.. 2022 , 166, 84-93	0
763	Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy.. 2022 , 106, 108617	0
762	Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.. 2021 , 10,	0
761	T cell receptor (TCR) signaling in health and disease.. 2021 , 6, 412	9
760	A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).. 2021 ,	3
759	Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. 2021 ,	1
758	Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study.. 2021 , 13,	2
757	NSCLC Immunotherapy and Related Rare Toxicities: A Monocentric Real-Life Experience. 2021 , 4, 115-119	
756	Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.. 2022 , 10, 441	0

755 Long-term control of generalized lung cancer with pembrolizumab. **2021**, 14, 171-174

754 Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.. **2022**, 22, e2

8

753 Non-Small Cell Lung Cancer in Older Adults with Frailty. **2022**, 319-339

752 Neurological complications of lung cancer. **2022**, 243-276

751 Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.. **2022**, 29, 10732748221076682

750 A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.. **2022**, 38, e28

1

749 Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer.. **2022**, 2022, 3224373

1

748 Biomarkers of response to PD-1 pathway blockade.. **2022**,

2

747 Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status. **2022**, 6,

746 Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age.. **2022**, 20, 38

1

745 Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer.. **2022**, 14,

2

744 Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.. **2022**, 10,

0

743 Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.. **2022**, 14,

3

742 Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.. **2022**, 11, 201-212

3

741 Identification of the Expression Patterns and Potential Prognostic Role of 5-Methylcytosine Regulators in Hepatocellular Carcinoma.. **2022**, 10, 842220

0

740 Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review.. **2022**, 14,

2

739 What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?. **2022**, 24, 451

738 Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data.. **2022**,

6

737	A Study on Immune Cell Infiltration in Lung Adenocarcinoma.. 2022,	0
736	The New Era of Immunotherapy in Gastric Cancer.. 2022, 14,	6
735	Nivolumab-DTPA-Based PD-1 Imaging Reveals Structural and Pathological Changes in Colorectal Carcinoma.. 2022, 10, 839756	1
734	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.. 2022, 11,	0
733	Differential expression of PD-L1 and PD-L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non-small cell lung cancer.. 2022, 47,	0
732	Navigational bronchoscopy specimens and PD-L1 expression: a retrospective study.. 2022, 14, 295-305	
731	A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy.. 2022, 9622802221080753	0
730	Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion.. 2022, 10781552221079356	0
729	Effective Combination Immunotherapy through Vessel Normalization Using a Cancer-Targeting Antiangiogenic PeptideâAntibody Hybrid. 2100151	
728	Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer.. 2022, 29, 1316-1325	1
727	Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer.. 2022, 14,	3
726	Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy.. 2022, 12, 820408	0
725	Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (â75 Years Old) With Non-Small-Cell Lung Cancer.. 2022, 13, 807575	1
724	Pembrolizumab weight based dosing âA call for policy change.	0
723	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma.. 2022, 1	2
722	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.. 2022, 89, 499	1
721	The prognostic value of the derived neutrophil-to-lymphocyte ratio (dNLR) in patients treated with immune checkpoint inhibitors.. 2022, 1	0
720	Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge.. 2022, 10,	1

- 719 Strategies for Manipulating T Cells in Cancer Immunotherapy.. **2022**,
- 718 PDL1 positivity rate between triple negative and non-luminal Her2+ cases. **2022**, 18,
- 717 Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.. **2022**, 1
- 716 Encorafenib plus binimetinib in patients with -mutant non-small cell lung cancer: Phase II PHAROS study design.. **2021**, 2
- 715 Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer.. **2021**, 12, 749461 1
- 714 A Bayesian Network Meta-Analysis of First-Line Treatments for Non-Small Cell Lung Cancer with High Programmed Death Ligand-1 Expression.. **2022**, 11, 0
- 713 Le rôle des ganglions lymphatiques drainant la tumeur ^lâle des immunothâpies. **2022**,
- 712 Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis.. **2022**, 1
- 711 Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours.. **2022**, 164, 95-104
- 710 Radiotherapy could increase the efficacy of immunotherapy in non-small cell lung cancer.
- 709 Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis.. **2022**, 14,
- 708 Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.. **2022**, 13, 274 2
- 707 Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.. **2022**, 13, 827921 4
- 706 Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy.. **2022**,
- 705 Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors.. **2022**, 45, 2
- 704 Clinicopathologic and molecular characteristics of -mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.. **2022**, 11, 452-461 0
- 703 Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.. **2022**, 11, 1
- 702 Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.. **2022**, 12, 859152 0

701	Integrative Analysis of Multi-Omics Data-Identified Key Genes With KLRC3 as the Core in a Gene Regulatory Network Related to Immune Phenotypes in Lung Adenocarcinoma.. 2022 , 13, 810193	0
700	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-analysis of 22 randomized controlled trials.. 2022 ,	
699	Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.. 2022 ,	0
698	First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.. 2022 ,	0
697	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.. 2022 , JCO2102010	10
696	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.. 2022 , 10,	1
695	Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?-A Comprehensive Review.. 2022 , 11,	1
694	Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer.	
693	The influence of transarterial chemoembolization on serum levels of soluble programmed cell death ligand-1 in advanced hepatocellular carcinoma patients.. 2022 ,	0
692	Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC.. 2022 ,	1
691	Cytomorphologic and immunophenotypical analysis of SMARCA4 (BRG1)-deficient non-small cell lung carcinoma.. 2022 ,	0
690	Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents.. 2022 , 10,	1
689	Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis.. 2022 , 3, 100309	0
688	PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.. 2022 ,	4
687	PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review.. 2022 ,	1
686	Predictive biomarkers for the efficacy of nivolumab as 3 rd -line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial.. 2022 , 22, 378	0
685	Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer.. 2022 , 1	1
684	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.. 2022 , 13, 830631	3

- 683 The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.. **2022**, 166, 143-149 0
- 682 TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy.. **2022**, 12, 860563 4
- 681 Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.. **2022**, 166, 205-220 0
- 680 Imaging immunity in patients with cancer using positron emission tomography.. **2022**, 6, 24 0
- 679 New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis.. **2022**, 10, 1
- 678 Gender Differences and Their Effects on Survival Outcomes in Lung Cancer Patients Treated With PD-1/PD-L1 Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.. **2022**, 0
- 677 Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.. **2022**, 7, 100445 1
- 676 Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis.. **2022**, 167, 49-57 2
- 675 Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.. **2022**, 19, 101383 0
- 674 The relationship between evolving sarcopenia and efficacy of immune checkpoint inhibitor in non-small cell lung cancer patients. **2021**, 6, 103-108
- 673 Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis. **2021**, 11, e049123 7
- 672 Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.. **2021**, 14, 2
- 671 The multi-specific V-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.. **2021**, 1
- 670 Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.. **2021**, 22, 2
- 669 Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.. **2021**, 23, 1
- 668 Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.. **2021**, 14, 0
- 667 B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.. **2021**, 2
- 666 Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma.. **2021**, 14, 1

665	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. 2021 , 12, 773168	1
664	Integrative Molecular Analyses of an Individual Transcription Factor-Based Genomic Model for Lung Cancer Prognosis.. 2021 , 2021, 5125643	
663	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.. 2021 , 14, 109	2
662	Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World.. 2021 , 2021, 3273347	0
661	Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials.. 2021 , 1-9	
660	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2
659	Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images.. 2021 , 2021, 5499385	1
658	Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of response to Immune Checkpoint Inhibitors in Gynecologic Cancers.. 2021 ,	1
657	Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data.. 2021 , 13,	2
656	Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy.. 2021 , 9, 1801	3
655	First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. 2021 , 13,	2
654	Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. 2021 , 11, e047663	
653	Effectiveness and safety of pembrolizumab monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer.. 2021 , 10781552211061117	
652	Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. 2021 ,	0
651	Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.. 2021 , 12, 734293	4
650	Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient.. 2021 ,	2
649	Anti-PD-1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report.. 2021 , 9, e05228	
648	Meta-Analysis of irAEs between Dose of CTLA-4 and PD-1 Inhibitors. 2021 ,	

- 647 Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung).. **2021**, 45, 0
- 646 Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer.. **2021**, 4, e2137508 5
- 645 A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice.. **2022**, 17, 53-60 0
- 644 GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response.. **2021**, 11, 733533 0
- 643 Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. **2021**, 4, 258-270 0
- 642 Optimizing immunoPET imaging of tumor PD-L1 expression: pharmacokinetics, biodistribution and dosimetric comparisons of Zr-labeled anti-PD-L1 antibody formats.. **2021**, 1
- 641 Relationship between Kita-Kyushu Lung Cancer antigen-1 expression and prognosis of cases with lung squamous cell carcinoma.. **2021**, 10, 5212-5221 0
- 640 A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab. **2021**, 2
- 639 Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review.. **2021**, 9, 1805 2
- 638 Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.. **2022**, 3, e137 0
- 637 Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.. **2022**, 0
- 636 The use of immunotherapy in older patients with advanced non-small cell lung cancer.. **2022**, 106, 102394 1
- 635 Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features.. **2022**, 13, 875093 0
- 634 Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer.. **2022**, 1 0
- 633 Classification of colorectal carcinoma subtypes based on ferroptosis-associated molecular markers.. **2022**, 20, 117 1
- 632 Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.. **2022**, 13, 862084 0
- 631 EGFR signaling pathway as therapeutic target in human cancers.. **2022**, 1
- 630 Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts.. **2022**, 1

629	Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer.. 2022 , 15,	1
628	Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.. 2022 ,	18
627	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.. 2022 , 5, e227722	1
626	High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis.. 2022 , 13, 866561	0
625	Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic.. 2022 , 12,	2
624	Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.. 2022 , 7, 100465	3
623	Data_Sheet_1.docx. 2020 ,	
622	Data_Sheet_1.docx. 2020 ,	
621	Data_Sheet_1.docx. 2020 ,	
620	Data_Sheet_1.docx. 2020 ,	
619	Table_1.docx. 2020 ,	
618	Table_2.docx. 2020 ,	
617	Table_3.docx. 2020 ,	
616	DataSheet_1.csv. 2020 ,	
615	Image_1.tif. 2020 ,	
614	Image_2.tif. 2020 ,	
613	Image_3.tif. 2020 ,	
612	Image_4.tif. 2020 ,	

611 Image_5.tif. **2020**,

610 Image_6.tif. **2020**,

609 Image_7.tif. **2020**,

608 Image_8.tif. **2020**,

607 Image_9.tif. **2020**,

606 Data_Sheet_1.docx. **2019**,

605 Data_Sheet_1.docx. **2019**,

604 Image_1.JPEG. **2019**,

603 Image_2.JPEG. **2019**,

602 Table_1.DOC. **2019**,

601 Table_1.docx. **2019**,

600 Data_Sheet_1.CSV. **2020**,

599 Data_Sheet_2.doc. **2020**,

598 Image_1.TIF. **2020**,

597 Image_2.TIF. **2020**,

596 Image_3.TIF. **2020**,

595 Image_4.TIF. **2020**,

594 Image_5.TIF. **2020**,

593 Image_6.TIF. **2020**,

592 Image_7.TIF. **2020**,

591 Image_8.PNG. **2020**,

590 Data_Sheet_1.docx. **2020**,

589 Data_Sheet_1.pdf. **2020**,

588 Table_2.xlsx. **2020**,

587 Table_3.xlsx. **2020**,

586 DataSheet_1.pdf. **2019**,

585 Image_1.pdf. **2020**,

584 Image_2.pdf. **2020**,

583 Data_Sheet_1.docx. **2018**,

582 Table_1.DOCX. **2020**,

581 Data_Sheet_1.doc. **2019**,

580 Data_Sheet_1.PDF. **2019**,

579 Image_1.tif. **2020**,

578 Image_2.tif. **2020**,

577 Image_1.TIF. **2019**,

576 Image_2.TIFF. **2019**,

575 Image_3.TIF. **2019**,

574 Table_1.DOCX. **2019**,

573 Table_10.DOCX. **2019**,

572 Table_11.DOCX. **2019**,

571 Table_12.docx. **2019**,

570 Table_2.DOCX. **2019**,

569 Table_3.DOCX. **2019**,

568 Table_4.DOCX. **2019**,

567 Table_5.docx. **2019**,

566 Table_6.DOCX. **2019**,

565 Table_7.DOCX. **2019**,

564 Table_8.DOCX. **2019**,

563 Table_9.DOCX. **2019**,

562 Data_Sheet_1.zip. **2020**,

561 Image_1.TIF. **2020**,

560 Image_2.TIF. **2020**,

559 Table_1.DOCX. **2020**,

558 Table_2.DOCX. **2020**,

557 Table_3.docx. **2020**,

556 Data_Sheet_1.docx. **2019**,

555 Data_Sheet_1.pdf. **2019**,

554 Presentation_1.PPTX. **2019**,

553 Data_Sheet_1.docx. **2020**,

552 Table_1.XLSX. **2020**,

551 DataSheet_1.pdf. **2019**,

550 Data_Sheet_1.PDF. **2019**,

549 Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?. **2022**, 17, 592-595

548 Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma.. **2022**,

4

547 Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors.. **2022**,

1

546 [Response of Lung Adenocarcinoma Harboursing Sensitizing EGFR Mutation?to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib]. **2021**, 24, 739-742

0

545 [Research Progress, Benefit Groups, Treatment Cycle and Efficacy Prediction ?of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer].. **2022**, 25, 92-101

544 [Research Progress of Immunotherapy for Non-small Cell Lung Cancer ?with Drive Gene Mutation].. **2022**, 25, 201-206

543 Clinicopathological aspects of V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small cell lung carcinoma in an Indian cohort: is there a difference?. **2021**, 12, 112-119

542 De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.. **2022**, 12, 123-137

1

541 Wnt2b and Wnt5a Expressions are Highly Associated with M2 TAMs in Non-Small Cell Lung Cancer.

540 Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer.. **2022**, 16, 11795549221092747

0

- 539 Current status and advances of immunotherapy in nasopharyngeal carcinoma.. **2022**, 14, 17588359221096214 ○
- 538 Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.. **2022**, 11, 670-685 ○
- 537 PD-1/PD-L1 co-location: A novel biomarker for immunotherapy response in non-small cell lung cancer.. **2022**,
- 536 Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model.. **2022**, 13, 829634 ○
- 535 Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. **2022**, 15, 533 1
- 534 A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study.. **2022**, 13, 859323 ○
- 533 A New AI-assisted Scoring System for PD-L1 expression in NSCLC. **2022**, 106829 ○
- 532 Current Status and Prospects of Perioperative Treatment with Immune Checkpoint Inhibitors for Resectable Non-Small Cell Lung Cancer. **2022**, 73, 83-86
- 531 Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.. **2022**, 13, 859013 ○
- 530 Concurrent high PD-L1 expression and CD8+ immune cell infiltration predict PD-1 blockade efficacy in advanced EGFR-mutant NSCLC patients. **2022**, ○
- 529 COMMD2 Upregulation Mediated by an ncRNA Axis Correlates With an Unfavorable Prognosis and Tumor Immune Infiltration in Liver Hepatocellular Carcinoma.. **2022**, 12, 853026 ○
- 528 Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.. **2022**, 14, 1
- 527 ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.. **2022**, 20, 170 1
- 526 Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies. ○
- 525 Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.. **2022**, 14, 2
- 524 Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review. **2022**, 12,
- 523 Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. **2022**, ○
- 522 Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study.. **2022**, 13, 686-693 1

521	Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis.. 2022 , 105403	
520	Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.. 2022 , 17, e0268288	1
519	Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.. 2022 , 54, 1339-1349	0
518	The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials.. 2022 , 174, 103700	0
517	Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.. 2022 , 169, 106-122	1
516	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.. 2022 , 12, 876098	0
515	Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. 2022 , 19, 5999	
514	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).. 2022 , 1	
513	Prognostic value of immunotherapy-induced organ inflammation assessed on FDG PET in patients with metastatic non-small cell lung cancer.. 2022 , 1	
512	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.. 2022 , 7, 100474	1
511	Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.. 2022 , 170, 17-26	1
510	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).. 2022 , JCO2102660	10
509	The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. 2022 , 13,	1
508	An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma.. 2022 , 12, 8230	
507	A novel four-gene signature predicts immunotherapy response of patients with different cancers.. 2022 , e24494	1
506	The role of biomarkers in personalized immunotherapy.. 2022 , 10, 32	3
505	Biomarkers for Cancer Immunotherapy. 2022 , 229-247	
504	Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. 2022 ,	3

- 503 Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. **2022**, 0
- 502 Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. **2022**, 23, 5731 1
- 501 Added Value of Respiratory Gating in Positron Emission Tomography for the Clinical Management of Lung Cancer Patients. **2022**, 1
- 500 Pembrolizumab Weight-Based Dosing: Conviction and Lacunae in Adopting a Cost-Saving Approachâ Survey Report.
- 499 Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. **2022**, 10, 1181 1
- 498 Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study. **2022**, 22,
- 497 Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. **2022**, 12, 0
- 496 Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review. **2022**, 10, 1237 0
- 495 Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India. **2022**,
- 494 HLA-I diversity and Tumor Mutational Burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. **2022**, 0
- 493 Traitement de 1re ligne des CBNPC mtastatiques sans addiction oncognrique. **2022**, 14, 1S52-1S67
- 492 Immune checkpoint inhibitors alone vs immune checkpoint inhibitorscombined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis. 0
- 491 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. **2022**, 10, e003956 0
- 490 Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. 13, 1
- 489 Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. 13, 1
- 488 Adverse effects under immune checkpoint inhibitors on 18F-FDG PET/CT imaging. 0
- 487 Estimating the replicability of highly cited clinical research (2004-2018).
- 486 Combination of Stereotactic Ablative Radiotherapy With Anti-PD-1 in Oligoprogressive Non-Small-Cell Lung Cancer And Melanoma: Results of a Prospective Multicenter Observational Study. **2022**, 0

- 485 FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. **2022**, o
- 484 Real-world Outcomes of Pembrolizumab Monotherapy in Non-Small Cell Lung Cancer in Japan: a Post-marketing Surveillance.
- 483 Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis. o
- 482 Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. 12, o
- 481 Prediction of lung cancer immunotherapy response via machine learning analysis of immune cell lineage and surface markers. **2022**, 1-12
- 480 Case Report: First-Line Immune Checkpoint Inhibitor Plus Chemotherapy for Oral Metastasis in a Patient with Ultra High-Risk Gestational Choriocarcinoma. Volume 14, 1867-1875 o
- 479 Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. 1
- 478 Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. **2022**, 41, 4
- 477 When immunotherapy meets surgery in non-small cell lung cancer. **2022**, o
- 476 Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer. **2022**, 102, 493-498
- 475 Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN). **2022**, 14, 2782 o
- 474 Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study. **2022**, o
- 473 Targeted therapies in non-small cell lung cancer and the potential role of AI interventions in cancer treatment. o
- 472 Multi-Omics Integrative Analysis of Lung Adenocarcinoma: An in silico Profiling for Precise Medicine. 9, o
- 471 Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.
- 470 Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. **2022**, 100355 o
- 469 A Meta-Analysis of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer. **2022**, 12, 4692-4699
- 468 PD-1/L1 With or Without CTLA-4 Inhibitors Versus Chemotherapy in Advanced Non-Small Cell Lung Cancer. **2022**, 29, 107327482211075 o

- 467 Modern treatment of ALK-positive non-small cell lung cancer. **2022**, 3, 41-51
- 466 The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. 12,
- 465 First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer.
- 464 MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. 1
- 463 Current Status and Future Directions of Bacteria-Based Immunotherapy. 13, 1
- 462 Radiopharmaceuticals as Novel Immune System Tracers. **2022**, 100936
- 461 Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. **2022**, 27, 3798 5
- 460 Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors. **2022**, 2022, 1-9
- 459 A unified framework for weighted parametric group sequential design. 0
- 458 First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score $\geq 10\%$) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). 1
- 457 Dynamic changes of peripheral NK cells predict outcome in patients with PD-L1 positive Non-Small-Cell Lung Cancer undergoing immune checkpoint inhibitors as second-line therapy. 1-31
- 456 PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. **2022**, 12, 1
- 455 Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. **2022**, 11, 3245 1
- 454 Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. 9
- 453 Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. 0
- 452 Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment. 13,
- 451 Resveratrol in cancer treatment with a focus on breast cancer. **2022**, 15,
- 450 Two-year efficacy of SNK01 plus pembrolizumab for non-small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial. 0

- 449 Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study. **2022**, 10
- 448 Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. *thoraxjnl-2020-215614* 0
- 447 Treatment Considerations for Patients with Advanced Squamous Cell Carcinoma of the Lung. **2022**, 1
- 446 A phase 2 study of docetaxel, ramucirumab, and pembrolizumab for patients with metastatic or recurrent non-small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade.. **2022**, 0
- 445 Tumor Microenvironmentâ Short Review of Cellular and Interaction Diversity. **2022**, 11, 929 2
- 444 Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. 15
- 443 Checkpoint inhibitors in non-small cell lung carcinoma therapy for progression to the brain (clinical observation). **2022**, 186-192
- 442 Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis. **2022**, 2
- 441 EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. **2022**, 23, 6489 1
- 440 Impact of Adding Vascular Endothelial Growth Factor Inhibitor to Immune Checkpoint Inhibitor Therapy. **2022**, 17, 865-866
- 439 Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. **2022**, 172, 85-95 2
- 438 The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure. **2022**, 34, 64-77
- 437 ICIs-Related Cardiotoxicity in Different Types of Cancer. **2022**, 9, 203 0
- 436 Immune checkpoint inhibitorsâcombination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis. 1
- 435 A review of concurrent chemo/radiation, immunotherapy, radiation planning, and biomarkers for locally advanced non-small cell lung cancer and their role in the development of ECOG-ACRIN EA5181. **2022**,
- 434 Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. 12,
- 433 Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. Publish Ahead of Print,
- 432 Identification of the Key miRNAs and Genes Associated with the Regulation of Non-Small Cell Lung Cancer: A Network-Based Approach. **2022**, 13, 1174

- 431 Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives. **2022**, 14, 3138
- 430 Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
- 429 18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. 1
- 428 Bronchialkarzinome â€“(k)eine MÃ¼rnerdomÃ¶ie. **2022**, 13, 115-115
- 427 Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer. **2022**, 2022, 1-11 0
- 426 Racial and ethnic trends and disparities in non-small cell lung cancer. **2022**, 100374
- 425 Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases. **2022**, 4,
- 424 The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer. 0
- 423 Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-27 0
- 422 Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. 0
- 421 Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab + ipilimumab. 1
- 420 Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma. 0
- 419 Clinically-meaningful improvements in therapy for unresectable NSCLC. 0
- 418 A Dramatic Response to Toripalimab With Chemotherapy and Antiangiogenic Agent Followed by Surgery in a Stage IIIB Lung Adenocarcinoma Patient With an Uncommon EGFR Mutation: A Case Report. 12,
- 417 Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. 0
- 416 Pulmonary adverse events following immune checkpoint inhibitors. Publish Ahead of Print, 0
- 415 High expression of fibroblast-activating protein is a prognostic marker in non-small cell lung carcinoma. 0
- 414 Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. **2022**, 14, 3440

413	TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy. 2022 , 14, 3382	
412	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. 2022 , 22,	0
411	HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. 2022 , 22,	0
410	Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched caseâcontrol study. <i>annrheumdis-2022-222186</i>	1
409	Immunosenescence, inflammaging, and cancer immunotherapy efficacy. 1-12	1
408	Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.	1
407	Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. 2022 , 14, 3473	1
406	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. 2022 , 14, 3337	2
405	Safety implications of switching pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W in patients with advanced non-small-cell lung cancer. 2022 ,	0
404	Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.	
403	Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. 2022 , 17, e0270832	0
402	Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. 2022 , 17, e0270950	
401	Applicability analysis of immunotherapy for lung cancer patients based on deep learning. 2022 , 205, 149-156	
400	Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.	0
399	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer.	1
398	Effets ind�sirables rhumatologiques des inhibiteurs de point de contr�le PD-(L)1 dans le cancer du poumon : revue syst�matique et m�ta-analyse. 2022 ,	
397	Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases. 12,	0
396	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. 13,	0

- 395 Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. ○
- 394 Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.
- 393 Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. **2022**, 14, 3568 ○
- 392 Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study. **2022**, 2022, 1-10 ○
- 391 Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report. **2022**, 10, 8284-8290 ○
- 390 Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis. **2022**, 11, 4373
- 389 Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. **2022**, 2022, 1-11
- 388 A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment. ○
- 387 Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis.
- 386 Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. 13,
- 385 Emerging Biomarkers and the Changing Landscape of Small Cell Lung Cancer. **2022**, 14, 3772 ○
- 384 Immunotherapy in non-small cell lung cancer: Past, present, and future directions. 12, 2
- 383 High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications. ○
- 382 Sex-specific T cell exhaustion drives differential immune responses in glioblastoma.
- 381 Immunohistochemical expression of CD8, CTLA4, and PD-L1 in NSCLC of smokers versus non smokers and its effect on prognosis. **2022**, 58, 92-101
- 380 A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORIG1630. ○
- 379 Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. 12, 1
- 378 Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China. 13,

- 377 A risk model including eight tumor microenvironment-related genes for prediction of lung cancer prognosis.
- 376 Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. **2022**, 5, e2227211 o
- 375 Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives. o
- 374 Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients. 12,
- 373 Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. 13, o
- 372 PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. 12, 1
- 371 Immune Checkpoint Inhibitors in Lung Cancer. 8, 111-120
- 370 Caspase-8 Contributes to Immuno-Hot Microenvironment by Promoting Phagocytosis via an Ecto-Calreticulin-dependent Mechanism.
- 369 KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. **2022**, 23, 9391 o
- 368 Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. 12, o
- 367 Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. **2022**, 33, 752-757
- 366 Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. 12, 2
- 365 Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti-PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients. 12, o
- 364 Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
- 363 Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Impact on Survival in Asian Patients. **2022**, o
- 362 Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. 13, 1
- 361 Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series. 9, o
- 360 What is the status of immunotherapy in thyroid neoplasms?. 13, o

- 359 Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12, 0
- 358 Special issue "The advance of solid tumor research in China" FGFR4 alterations predict efficacy of immune checkpoint inhibitors in non-small cell lung cancer.
- 357 Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer. 0
- 356 Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%. 12, 1
- 355 Immunotherapeutic targets in non-small cell lung cancer. 1
- 354 Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. 2022, 2022, 1-15
- 353 The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. 2022, 2022, 1-11
- 352 Spatial positioning and matrix programs of cancer-associated fibroblasts promote T cell exclusion in human lung tumors. 2
- 351 Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. 2022, 0
- 350 Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programmed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. 12,
- 349 Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. 12, 1
- 348 Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis. 13, 1
- 347 Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. 2022, 0
- 346 Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. 2022, 174, 113-120 0
- 345 Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-III A non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. 2022, 23, 1274-1286 8
- 344 The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. 2022, 7, 100577 0
- 343 Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer. 2022, 14, 1121-1131 0
- 342 Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. 2022, 173, 101-106 0

341	Chemotherapy for Lung Cancer. 2022 ,	o
340	Multi-omics analysis to identify lung squamous carcinoma lactate metabolism-related subtypes and establish related index to predict prognosis and guide immunotherapy. 2022 , 20, 4756-4770	o
339	Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. 2022 ,	o
338	Immunotherapy in Early Stage Non-Small Cell Lung Cancer. 2022 , 11, 31-44	o
337	Research Progress of Tumor Mutational Burden in Predicting Prognosis of Patients with Malignant Tumors. 2022 , 12, 7000-7004	o
336	Available Immunotherapy Drugs in Oncology. 2022 , 5-23	o
335	Interdisciplinary Approach in Lung Cancers. 2022 ,	o
334	Cost-Effectiveness of Pembrolizumab for the treatment of Nonâ€Small-Cell lung cancer: A systematic review. 12,	o
333	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.	2
332	Photodynamic therapy of lung cancer, where are we?. 13,	1
331	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after â€From lymphocytes induces PD-L1 expression and promotes progression of ovarian cancerâ€	1
330	Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review. 12,	o
329	Wnt2b and Wnt5a expression is highly associated with M2 TAMs in non-small cell lung cancer. 2022 , 48,	1
328	Immune status for monitoring and treatment of bladder cancer. 13,	o
327	Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. 2022 , 105457	o
326	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. 12,	o
325	Integrin alpha 2 is associated with tumor progression and postoperative recurrence in non-small cell lung cancer.	o
324	Association of Oncologist Participation in Medicareâ€Oncology Care Model With Patient Receipt of Novel Cancer Therapies. 2022 , 5, e2234161	o

323	Establishing a Novel Gene Signature Related to Histone Modifications for Predicting Prognosis in Lung Adenocarcinoma. 2022 , 2022, 1-19	0
322	Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment. 2022 , 11, 2793	0
321	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. 13,	0
320	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. 2022 , 14, 4562	1
319	Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis. 2022 ,	0
318	A Randomized Phase II Trial of Nivolumab versus Nivolumab-Ipilimumab Combination in EGFR-Mutant Non-Small Cell Lung Cancer. 2022 , 100416	0
317	Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. 12,	0
316	Integration of New Systemic Adjuvant Therapies for Non-Small Cell Lung Cancer: Role of the Surgeon. 2022 ,	0
315	Real-world data analysis of pembrolizumab monotherapy for non-small cell lung cancer utilizing Japanese post-marketing all-case surveillance data. 2022 , 100404	0
314	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. 2022 , 14, 4481	0
313	Editorial: Tumor microenvironment signaling networks in pathophysiology and therapeutics. 12,	0
312	The Interaction of the IFN γ /JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. 2022 , 2022, 1-16	0
311	Combination of Tumor Mutational Burden and DNA Damage Repair Gene Mutations with Stromal/Immune Scores Improved Prognosis Stratification in Patients with Lung Adenocarcinoma. 2022 , 2022, 1-12	0
310	Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis. 2022 , 6,	0
309	The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study. 13,	1
308	Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.	0
307	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. 13,	5
306	On-Target Side Effects of Targeted Therapeutics of Cancer. 28,	0

305	Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. 2022 , 19, 1153-1167	o
304	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. 2022 , 101, e30151	o
303	PD-L1 expression in lung cancer and paired brain metastases â single center study in 190 patients.. 2022 , 100413	o
302	Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.	o
301	The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression. 12,	o
300	Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review. 030089162211226	o
299	CT-based radiomics signature to predict CD8+ tumor infiltrating lymphocytes in non-small-cell lung cancer. 028418512211265	o
298	Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. 2022 , 14, 4759	o
297	Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng cancerR Extensive disease â randomized, open-label, multicenter phase II trial. 2022 , 22,	o
296	Biomarkers and immunotherapy: where are we?. 2022 , 34, 579-586	1
295	Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.	o
294	Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial. 2022 ,	o
293	Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development. 1-34	o
292	Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma. 2022 , 22,	o
291	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. 2022 , 7,	o
290	Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. 1-12	o
289	The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. 2022 ,	o
288	MTAP deficiency contributes to immune landscape remodeling and tumor evasion.	o

- 287 Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. 12, 1
- 286 Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?. **2022**, 17, 1155-1157 0
- 285 SOLT1-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. 1
- 284 Bifidobacterium breve predicts the efficacy of anti-PD -1 immunotherapy combined with chemotherapy in Chinese NSCLC patients. 0
- 283 Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. 13, 1
- 282 PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma. 13, 0
- 281 NMR-Based Metabolomics to Evaluate Individual Response to Treatments. **2022**, 0
- 280 Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. **2022**, 14, 175883592211338 0
- 279 Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. **2022**, 13, 0
- 278 Nivolumab-induced radiation recall pneumonitis in non-small cell lung cancer patients with thoracic radiation therapy. 0
- 277 Synthesis and preliminary evaluations of [18F]fluorinated pyridine-2-carboxamide derivatives for targeting PD-L1 in cancer. **2022**, 23, 0
- 276 History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. **2022**, 73, 325-331 0
- 275 Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis. **2022**, 0
- 274 The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic Driven Non-Small Cell Lung Cancer: A University of California Lung Cancer Consortium Retrospective Study. **2022**, 100427 0
- 273 Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study. 1-8 0
- 272 Outcomes of EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced EGFR-mutated non-small cell lung cancer. 0
- 271 Biomarqueurs en immunothérapie, signatures moléculaires, radiomique : avons-nous avancé?. **2022**, 14, 2S225-2S232 0
- 270 Algorithme thérapeutique des cancers bronchiques non à petites cellules tendus avec mutation de l'EGFR. **2022**, 14, 2S189-2S208 0

- 269 Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. 13, ○
- 268 Update on Immune Checkpoint Inhibitor Enterocolitis. ○
- 267 The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do not Receive Chemoradiation. Publish Ahead of Print, ○
- 266 Traitements systémiques du cancer bronchique non ^petites cellules chez les sujets âgés. **2022**, 14, 2S327-2S337 ○
- 265 Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?. **2022**, 11, 3280 ○
- 264 Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors. ○
- 263 Review on Advanced Cancer Modeling for a Cancer Study. **2022**, 44, 5352-5362 ○
- 262 Precision Medicine in Oncology Drug Development. 1-15 ○
- 261 PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. **2022**, 10, e004590 ○
- 260 Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis. **2022**, 22, ○
- 259 The Lung Microbiota and Lung Cancer: A Growing Relationship. **2022**, 14, 4813 ○
- 258 Cancer of the Lung. 1-29 ○
- 257 Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: a systematic review and Meta-analysis. ○
- 256 Algorithme thérapeutique des CBNPC sans mutation addictive. **2022**, 14, 2S165-2S177 ○
- 255 Predictive Factors for the Efficacy of Immune Checkpoint Inhibitors Against Lung Cancer. **2022**, 62, 355-362 ○
- 254 Immunotherapy and Modern Radiotherapy Technique for Older Patients with Locally Advanced Head and Neck Cancer: A Proposed Paradigm by the International Geriatric Radiotherapy Group. **2022**, 14, 5285 ○
- 253 More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance. ○
- 252 Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. **2022**, 10, e005248 ○

- 251 Analyse de la prise en charge des cancers bronchiques avec mutation du gène de l'EGFR. **2022**, ○
- 250 Molecular subtypes based on cuproptosis-related genes and immune profiles in lung adenocarcinoma. 13, ○
- 249 Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer. ○
- 248 Immune Checkpoint Inhibitors combined with HER-2 targeted therapy in HER-2 positive Gastroesophageal cancer. **2022**, 103864 ○
- 247 Genopathomic profiling identifies signatures for immunotherapy response of lung adenocarcinoma via confounder-aware representation learning. **2022**, 25, 105382 ○
- 246 Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report. **2022**, 16, ○
- 245 Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study. ○
- 244 Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer. **2022**, 2, ○
- 243 Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer. **2022**, 42, 1956-19742 ○
- 242 The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?. ○
- 241 A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma. 13, ○
- 240 Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. **2022**, 58, 1572 ○
- 239 Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma. jclinpath-2021-207795 ○
- 238 Datele din lumea reală - studiiile clinice pentru evaluarea eficacității noilor terapii oncologice. Rolul studiilor observaționale, cu exemplificare în cancerul pulmonar în celule mici (NSCLC). **2022**, 3, 23 ○
- 237 The heterogeneity effect of surveillance intervals on progression free survival. 1-18 ○
- 236 Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration. **2022**, 2022, 1-15 ○
- 235 Cost-effectiveness of first-line pembrolizumab monotherapy versus chemotherapy in high PD-L1 advanced non-small cell lung cancer in the Irish healthcare setting. **2022**, ○
- 234 CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types. 13, ○

233	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. 2022 , 14,	o
232	Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).	o
231	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. 13,	o
230	Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways. 2022 , 3, 100819	o
229	Comparison of 22C3-PD-L1 Expression Between Paired Tumor Paraffin Blocks of Surgical Resection Specimens of Nonsmall Cell Lung Cancer. Publish Ahead of Print,	o
228	Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. 12,	o
227	Abemaciclib in combination with pembrolizumab for HR+, HER2 ⁺ metastatic breast cancer: Phase 1b study. 2022 , 8,	1
226	Editorial: Impact of immunotherapy in lung cancer. 12,	o
225	Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. 2022 , 20,	o
224	The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma. 2022 , 174, 125-132	o
223	Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. 2022 , 8, 100202	o
222	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. 2022 ,	o
221	Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors.	1
220	A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer. 2022 , 101, e31751	o
219	Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. 2022 , 22,	o
218	Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature. 10, 12305-12312	o
217	A case of immune checkpoint inhibitor-related myocarditis induced by pembrolizumab for tongue cancer. 2022 , 68, 385-391	o
216	Research Progress of Intestinal Flora in the Treatment of Lung Cancer—Intestinal Flora and Lung Cancer. 2022 , 12, 10933-10941	o

- 215 Proteomic analysis of brain metastatic lung adenocarcinoma reveals intertumoral heterogeneity and specific alterations associated with the timing of brain metastases. **2023**, 8, 100741 1
- 214 Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation. **2023**, 28, 101603 0
- 213 Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients. **2023**, 9, 100209 0
- 212 The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. **2022**, 0
- 211 Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. **2022**, 14, 175883592211440 0
- 210 Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. **2022**, 117, 1917-1932 0
- 209 Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis. **2022**, 22, 1
- 208 Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 and 2020 - A population-based registry study from Norway. 12, 0
- 207 Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer. **2022**, 8, 0
- 206 Design and reporting of phase III oncology trials with prospective biomarker validation. 0
- 205 An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. 13, 1
- 204 Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. 12, 0
- 203 A Review of the Role of Stereotactic Radiosurgery and Immunotherapy in the Management of Primary Central Nervous System Tumors. **2022**, 10, 2977 0
- 202 Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. **2022**, 24, 269-304 0
- 201 Radiotherapy of the Primary Disease for Synchronous Metastatic Cancer: A Systematic Review. **2022**, 14, 5929 0
- 200 Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. 12, 0
- 199 Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. **2022**, 23, 14496 1
- 198 Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report. **2022**, 16, 0

197	A Comparison of Patients' and Physicians' Knowledge and Expectations Regarding Precision Oncology Tests. 2022 , 29, 9916-9927	o
196	Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. 2022 ,	o
195	Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy. 13,	o
194	Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. 2022 , 14, 6095	1
193	PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study. 13,	o
192	Checkpoint inhibitors are a basic science-based, transformative new treatment for lung cancer.	o
191	Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. 2022 , 10, e005436	o
190	Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. 2022 , 23, e552-e561	1
189	Role of Immunosuppressive and Immunomodulatory Agents in Cancer.	o
188	First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia. 2022 , 12-20	o
187	Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer.	o
186	Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.	o
185	Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review. 2022 , 11, 7176	o
184	Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. 2022 , 22,	o
183	In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF- κ B modulator in lung cancer. 2022 , 12,	o
182	Macrophage GSK3 β deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. 2022 , 10, e005655	o
181	Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. 2022 , 10, e004952	o
180	Case report: Eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on 18F-FDG-PET/CT. 9,	o

- 179 Consolidative high-dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo-progressive disease. ○
- 178 Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. **2022**, 1
- 177 Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. **2022**, 14, 6145 ○
- 176 Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study. **2022**, 100934 ○
- 175 Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study. ○
- 174 Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. **2022**, 15, 1
- 173 Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center. ○
- 172 Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. 13, ○
- 171 Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives. ○
- 170 The Spectrum of Infections in Patients with Lung Cancer. 1-18 ○
- 169 The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study. **2022**, 14, 6184 ○
- 168 Impact of Federal Lung Cancer Screening Policy on the Incidence of Early-stage Lung Cancer. **2022**, ○
- 167 Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. Volume 16, 4269-4277 ○
- 166 Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials. ○
- 165 Model-based meta-analysis of non-small cell lung cancer with standard-of-care PD -1 inhibitors and chemotherapy for early development decision making. ○
- 164 Clinical Progress and Prospect of Traditional Chinese Medicine Combined with Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer. **2022**, 12, 11735-11739 ○
- 163 CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report. **2023**, ○
- 162 Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors. ○

161	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.	0
160	Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC. 2023 , 23,	0
159	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. 2023 , 15, 329	0
158	Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. 13,	0
157	Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism. 2023 , 12,	0
156	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.	1
155	EGFR-Directed Therapy in Lung Cancer. 2023 ,	0
154	Advances in artificial intelligence to predict cancer immunotherapy efficacy. 13,	0
153	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. 13,	0
152	Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma. 14,	0
151	Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. 2023 , 13, 167	1
150	Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. 14,	0
149	Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upâ 2023 ,	0
148	A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.	0
147	Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer. 2023 ,	0
146	The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small -cell lung cancer.	0
145	The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.	0
144	Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. 12,	0

- 143 Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous Non-Small Cell Lung Cancer. **2023**, 100461 ○
- 142 Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?. **2023**, 269-287 ○
- 141 Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. **2023**, 857, 147177 ○
- 140 The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations. 1-15 ○
- 139 Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. ○
- 138 Long Non-Coding RNAs as Epigenetic Regulators of Immune Checkpoints in Cancer Immunity. **2023**, 15, 184 ○
- 137 Atypical Response in Metastatic Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: Radiographic Patterns and Clinical Value of Local Therapy. **2023**, 15, 180 ○
- 136 Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group. **2023**, 15, 244 ○
- 135 Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma. **2023**, 13, 49 ○
- 134 Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients. **2022**, ○
- 133 Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. **2023**, 11, 83 ○
- 132 Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. **2023**, 24, 599 ○
- 131 The influence of drug-eluting beads transarterial chemoembolization on serum levels of soluble programmed cell death protein-1 in advanced hepatocellular carcinoma patients. ○
- 130 Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards. **2023**, ○
- 129 Tumor immunology. **2023**, 245-452 ○
- 128 Prediction of Risk and Clinical Outcome of cuproptosis in Lung Squamous carcinoma. ○
- 127 Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance. 1-12 ○
- 126 Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. **2023**, 15, 689 ○

125	Pulmonary Side Effects of Immunotherapy. 2023 , 1-13	o
124	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study.	1
123	Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. 2023 , 11, e005007	o
122	Comparison of ASCL1 , NEUROD1 , and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.	o
121	Assessing PD-L1 Expression in Different Tumor Types. 2023 , 1-21	o
120	A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. 12,	o
119	Immunotherapy for older patients with cancer. 2023 , 17, 37-46	o
118	Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics. 2023 , 13,	o
117	Imaging the immune cell in immunotherapy. 2023 , 197-238	o
116	Associated Factors of Spontaneous Hemorrhage in Brain Metastases in Patients with Lung Adenocarcinoma. 2023 , 15, 619	o
115	Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis.	o
114	Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC. 2023 ,	o
113	Editorial: Factors that impact the survival of non-small cell lung cancer. 13,	o
112	Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors. 2023 , 15, 1382	o
111	The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. 2023 ,	o
110	Targeted Therapy for Non-small Cell Lung Cancer. 2023 ,	o
109	Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer. 2023 ,	o
108	Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study. 13,	o

- 107 Immunotherapy-based combinations in metastatic NSCLC. **2023**, 116, 102545 o
- 106 Fuzheng Kang-Ai inhibits NSCLC cell proliferation via regulating hsa_circ_0048091/hsa-miR-378g/ARRDC3 pathway. **2023**, 114, 154819 o
- 105 Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer. **2023**, 33, 189-196 o
- 104 Qualitative analysis of PD-L1 expression in non-small-cell lung cancer based on chest CT radiomics. **2023**, 84, 104815 o
- 103 Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: A new milestone. 13, o
- 102 Pathologische Grundlagen und Anforderungen. **2022**, 25-58 o
- 101 Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018. **2023**, 183, 38-48 o
- 100 Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India. o
- 99 Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens. o
- 98 Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report. 14, o
- 97 Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. 13, o
- 96 Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. **2023**, 14, o
- 95 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 o
- 94 Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. **2023**, 153, 40039 o
- 93 Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. **2023**, 13, o
- 92 Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. **2023**, o
- 91 Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. **2023**, 11, 508 o
- 90 Functional binding of PD1 ligands predicts response to anti-PD1 treatment in cancer patients. o

- 89 Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. **2023**, 24, 3618 ○
- 88 Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial. **2023**, 178, 183-190 ○
- 87 Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. **2023**, 30, 2366-2387 ○
- 86 Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention. 14, ○
- 85 Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. **2023**, 2, 65-78 ○
- 84 Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. **2023**, 23, 1
- 83 Lung cancer immunotherapy: progress, pitfalls, and promises. **2023**, 22, ○
- 82 Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer. ○
- 81 Association Between Survival and Metastatic Site in Mismatch RepairâDeficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. **2023**, 6, e230400 ○
- 80 Changes in the urine proteome in patients with advanced lung cancer after different drug treatments. **2023**, 5, 1-12 ○
- 79 Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. **2023**, 102, e32899 ○
- 78 Non-small cell lung cancer: news from immunotherapy. **2022**, 9, 8-10 ○
- 77 Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL). **2023**, 4, 100484 ○
- 76 Immune-related adverse events as potential surrogates of immune checkpoint inhibitorsâefficacy: a systematic review and meta-analysis of randomized studies. **2023**, 8, 100787 ○
- 75 Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer. **2023**, 42, 101824 ○
- 74 CD169 + sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer. ○
- 73 Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. **2023**, 12, 1833 ○
- 72 Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. **2023**, 8, 100784 ○

- 71 Correlation of 18F-FDG PET/CT metabolic parameters with the expression of immune biomarkers in the tumour microenvironment in lung adenocarcinoma. **2023**, ○
- 70 Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review. **2023**, 15, 175883592311568 ○
- 69 Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. ○
- 68 Precision Surgery in NSCLC. **2023**, 15, 1571 ○
- 67 Antitumor Therapy Targeting the Tumor Microenvironment. **2023**, 2023, 1-16 ○
- 66 Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. **2023**, 8, 101160 ○
- 65 CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. **2023**, 14, ○
- 64 Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. **2023**, 184, 103954 ○
- 63 Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. 14, ○
- 62 Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. 14, ○
- 61 Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments. 14, ○
- 60 Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. **2023**, 13, ○
- 59 Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma. 14, ○
- 58 Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. **2023**, 13, ○
- 57 Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer. 14, ○
- 56 Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy. **2023**, 356, 360-372 ○
- 55 Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. **2023**, 7, 273-284 ○
- 54 Anti-PD-(L)1 therapy of non-small cell lung cancer—a summary of clinical trials and current progresses. **2023**, 9, e14566 ○

- 53 Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥50% in Patients Treated in Québecâ University Teaching Hospitals (DALP-First Study). **2023**, 30, 3251-3262 o
- 52 Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. 14, o
- 51 Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions. o
- 50 High Interobserver Variability among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction and Esophageal Adenocarcinoma. **2023**, 100154 o
- 49 Association of Glycosylation-Related Genes with Different Patterns of Immune Profiles and Prognosis in Cervical Cancer. **2023**, 13, 529 o
- 48 PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers. o
- 47 Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test. **2023**, 36, 100159 o
- 46 Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study. 13, o
- 45 NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know. **2023**, 13, 1117 o
- 44 Nanomedicine in Lung Cancer Immunotherapy. 11, o
- 43 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. **2023**, 15, 175883592311614 o
- 42 Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors. o
- 41 Theranostic applications of selenium nanomedicines against lung cancer. **2023**, 21, o
- 40 Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. **2023**, 24, 5938 o
- 39 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16, o
- 38 Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. **2023**, 15, 1909 o
- 37 Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. 13, o
- 36 Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). **2023**, 8, 101192 o

- 35 Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer. 14, ○
- 34 Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma. **2023**, 35, 166-177 ○
- 33 The Value of Comprehensive Molecular Profiling in Early Stage Lung Cancer. **2023**, 18, 393-395 ○
- 32 Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. **2023**, 15, 1968 ○
- 31 Date de tip real world privind utilizarea nivolumabului în cancerul pulmonar nonmicrocelular avansat în linco de linia a doua. Experiența noastră în România imediat după rambursarea imunoterapiei prin sistemul național de sănătate. **2023**, 1, 32 ○
- 30 Oncogenic epidermal growth factor receptor signal-induced histone deacetylation suppresses chemokine gene expression in human lung adenocarcinoma. **2023**, 13, ○
- 29 Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer. ○
- 28 Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. **2023**, 14, ○
- 27 Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. **2023**, ○
- 26 Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. ○
- 25 Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. 14, ○
- 24 Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. ○
- 23 Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy. ○
- 22 Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. **2023**, 11, 1073 ○
- 21 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 20 Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. ○
- 19 Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression. **2023**, 33, 101671 ○
- 18 Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. **2023**, 15, 1252 ○

- 17 Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions. **2023**, 562, 216182 ○
- 16 Multi-omics analysis reveals prognostic and immune characteristics of cuproptosis in lung adenocarcinoma. ○
- 15 Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. **2023**, 13, 37-43 ○
- 14 Radiation Biology of Lung Cancer. **2023**, ○
- 13 Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC. **2023**, 14, 151-161 ○
- 12 CodeBreakK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code. Volume 14, 31-39 ○
- 11 The Value of Peripheral Blood Index in the Evaluation of Curative Effect of Advanced Non-Small Cell Lung Cancer. **2023**, 13, 5979-5988 ○
- 10 Immunotherapy in glioblastoma treatment: Current state and future prospects. 14, 138-159 ○
- 9 Biomarker-based Bayesian randomized clinical trial design for identifying a target population. ○
- 8 Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. **2023**, 24, 7577 ○
- 7 Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia. **2023**, 13, ○
- 6 Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis. ○
- 5 Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?. **2023**, 12, 3014 ○
- 4 Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial. **2023**, 12, 1246 ○
- 3 Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. **2023**, 1-34 ○
- 2 Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients. 13, ○
- 1 Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. ○